KR101570123B1 - Cosmetic Composition Comprising Extract of testa of Pinus koraiensis Siebold et Zucc - Google Patents
Cosmetic Composition Comprising Extract of testa of Pinus koraiensis Siebold et Zucc Download PDFInfo
- Publication number
- KR101570123B1 KR101570123B1 KR1020140105250A KR20140105250A KR101570123B1 KR 101570123 B1 KR101570123 B1 KR 101570123B1 KR 1020140105250 A KR1020140105250 A KR 1020140105250A KR 20140105250 A KR20140105250 A KR 20140105250A KR 101570123 B1 KR101570123 B1 KR 101570123B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- pine
- acid
- skin
- concentration
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 186
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 239000002537 cosmetic Substances 0.000 title claims abstract description 29
- 240000007263 Pinus koraiensis Species 0.000 title abstract description 9
- 235000011615 Pinus koraiensis Nutrition 0.000 title abstract description 8
- 230000037303 wrinkles Effects 0.000 claims abstract description 27
- 230000002087 whitening effect Effects 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 230000006872 improvement Effects 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 62
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 61
- 235000011613 Pinus brutia Nutrition 0.000 claims description 61
- 241000018646 Pinus brutia Species 0.000 claims description 61
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 58
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000000839 emulsion Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 14
- 239000006071 cream Substances 0.000 claims description 11
- 230000032683 aging Effects 0.000 claims description 9
- 239000006210 lotion Substances 0.000 claims description 7
- 235000016709 nutrition Nutrition 0.000 claims description 5
- 230000003712 anti-aging effect Effects 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 240000004971 Pseudosasa japonica Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 59
- 230000003078 antioxidant effect Effects 0.000 abstract description 31
- 239000003963 antioxidant agent Substances 0.000 abstract description 20
- 235000006708 antioxidants Nutrition 0.000 abstract description 20
- 235000013305 food Nutrition 0.000 abstract description 15
- 239000000463 material Substances 0.000 abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 10
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 2
- 230000002500 effect on skin Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 66
- -1 polyoxyethylene Polymers 0.000 description 59
- 210000003491 skin Anatomy 0.000 description 54
- 235000014571 nuts Nutrition 0.000 description 52
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 48
- 230000002401 inhibitory effect Effects 0.000 description 48
- 102000003425 Tyrosinase Human genes 0.000 description 39
- 108060008724 Tyrosinase Proteins 0.000 description 39
- 108090000623 proteins and genes Proteins 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 32
- 244000184734 Pyrus japonica Species 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 26
- 108010035532 Collagen Proteins 0.000 description 24
- 102000008186 Collagen Human genes 0.000 description 24
- 229920001436 collagen Polymers 0.000 description 24
- 239000000469 ethanolic extract Substances 0.000 description 24
- 230000008099 melanin synthesis Effects 0.000 description 23
- 102000004190 Enzymes Human genes 0.000 description 22
- 108090000790 Enzymes Proteins 0.000 description 22
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 22
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 22
- 238000005259 measurement Methods 0.000 description 22
- 235000013824 polyphenols Nutrition 0.000 description 21
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 20
- 229940088598 enzyme Drugs 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 description 19
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 19
- 238000002835 absorbance Methods 0.000 description 18
- 102000029816 Collagenase Human genes 0.000 description 17
- 108060005980 Collagenase Proteins 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 17
- 229960002424 collagenase Drugs 0.000 description 17
- 235000014113 dietary fatty acids Nutrition 0.000 description 17
- 239000000194 fatty acid Substances 0.000 description 17
- 229930195729 fatty acid Natural products 0.000 description 17
- 230000005764 inhibitory process Effects 0.000 description 17
- 239000000758 substrate Substances 0.000 description 16
- 240000003296 Petasites japonicus Species 0.000 description 15
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 14
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 14
- 239000002253 acid Substances 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 201000001441 melanoma Diseases 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 12
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- 239000012488 sample solution Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000007796 conventional method Methods 0.000 description 10
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 10
- 210000002950 fibroblast Anatomy 0.000 description 10
- ACXGEQOZKSSXKV-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O.CCCCCCCC(O)=O ACXGEQOZKSSXKV-UHFFFAOYSA-N 0.000 description 10
- 150000002989 phenols Chemical class 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 102000013382 Gelatinases Human genes 0.000 description 9
- 108010026132 Gelatinases Proteins 0.000 description 9
- 102000016387 Pancreatic elastase Human genes 0.000 description 9
- 108010067372 Pancreatic elastase Proteins 0.000 description 9
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 9
- 239000003755 preservative agent Substances 0.000 description 9
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 8
- 208000003351 Melanosis Diseases 0.000 description 8
- 108010050808 Procollagen Proteins 0.000 description 8
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 8
- 102000040945 Transcription factor Human genes 0.000 description 8
- 108091023040 Transcription factor Proteins 0.000 description 8
- 239000003925 fat Substances 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 210000002752 melanocyte Anatomy 0.000 description 7
- 239000000049 pigment Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 208000012641 Pigmentation disease Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000036570 collagen biosynthesis Effects 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 238000004042 decolorization Methods 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- VFSWRBJYBQXUTE-UHFFFAOYSA-N epi-Gallocatechin 3-O-gallate Natural products Oc1ccc2C(=O)C(OC(=O)c3cc(O)c(O)c(O)c3)C(Oc2c1)c4cc(O)c(O)c(O)c4 VFSWRBJYBQXUTE-UHFFFAOYSA-N 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000002335 preservative effect Effects 0.000 description 6
- 108010029690 procollagenase Proteins 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 5
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 5
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 5
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 5
- 102000016942 Elastin Human genes 0.000 description 5
- 108010014258 Elastin Proteins 0.000 description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- 235000019438 castor oil Nutrition 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 230000011382 collagen catabolic process Effects 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 230000002849 elastaseinhibitory effect Effects 0.000 description 5
- 229920002549 elastin Polymers 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
- 208000000069 hyperpigmentation Diseases 0.000 description 5
- 230000003810 hyperpigmentation Effects 0.000 description 5
- 239000001023 inorganic pigment Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229940057995 liquid paraffin Drugs 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 description 5
- 229920002554 vinyl polymer Polymers 0.000 description 5
- 230000037373 wrinkle formation Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 4
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- ZCTQGTTXIYCGGC-UHFFFAOYSA-N Benzyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 ZCTQGTTXIYCGGC-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 4
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 4
- 206010014970 Ephelides Diseases 0.000 description 4
- 108700039887 Essential Genes Proteins 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102100030411 Neutrophil collagenase Human genes 0.000 description 4
- 239000002033 PVDF binder Substances 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 206010051246 Photodermatosis Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 4
- 239000003602 elastase inhibitor Substances 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 235000019388 lanolin Nutrition 0.000 description 4
- 229940039717 lanolin Drugs 0.000 description 4
- 229960004502 levodopa Drugs 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 230000008845 photoaging Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000037394 skin elasticity Effects 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 229940032094 squalane Drugs 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 3
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 3
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- GECRRQVLQHRVNH-MRCUWXFGSA-N 2-octyldodecyl (z)-octadec-9-enoate Chemical compound CCCCCCCCCCC(CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC GECRRQVLQHRVNH-MRCUWXFGSA-N 0.000 description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 206010008570 Chloasma Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 235000019482 Palm oil Nutrition 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- LNTHITQWFMADLM-UHFFFAOYSA-N anhydrous gallic acid Natural products OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229910000423 chromium oxide Inorganic materials 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 3
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000028023 exocytosis Effects 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- XDOFQFKRPWOURC-UHFFFAOYSA-N iso-octadecanoic acid Natural products CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 3
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 3
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 3
- 229960004705 kojic acid Drugs 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000010445 mica Substances 0.000 description 3
- 229910052618 mica group Inorganic materials 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000012860 organic pigment Substances 0.000 description 3
- 239000002540 palm oil Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 229940096998 ursolic acid Drugs 0.000 description 3
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- DEQUKPCANKRTPZ-UHFFFAOYSA-N (2,3-dihydroxyphenyl)-phenylmethanone Chemical compound OC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1O DEQUKPCANKRTPZ-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
- FTZIQBGFCYJWKA-UHFFFAOYSA-N 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 FTZIQBGFCYJWKA-UHFFFAOYSA-N 0.000 description 2
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 2
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 2
- ODMZDMMTKHXXKA-QXMHVHEDSA-N 8-methylnonyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCCCCCCC(C)C ODMZDMMTKHXXKA-QXMHVHEDSA-N 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 229940122858 Elastase inhibitor Drugs 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 101710118230 Neutrophil collagenase Proteins 0.000 description 2
- 108030001564 Neutrophil collagenases Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 244000062720 Pennisetum compressum Species 0.000 description 2
- 240000007320 Pinus strobus Species 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 241000206609 Porphyra Species 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- WUBKCBOQNXUQDU-UHFFFAOYSA-N [2-(dihydroxymethoxy)phenyl]-phenylmethanone Chemical compound OC(O)OC1=CC=CC=C1C(=O)C1=CC=CC=C1 WUBKCBOQNXUQDU-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003212 astringent agent Substances 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 230000008687 biosynthesis inhibition Effects 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 2
- MVLVMROFTAUDAG-UHFFFAOYSA-N ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC MVLVMROFTAUDAG-UHFFFAOYSA-N 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000010903 husk Substances 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- IGGVVGHJSQSLFO-UHFFFAOYSA-N indole-5,6-quinone Chemical compound O=C1C(=O)C=C2C=CNC2=C1 IGGVVGHJSQSLFO-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003061 melanogenesis Effects 0.000 description 2
- 210000002780 melanosome Anatomy 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- VBEGHXKAFSLLGE-UHFFFAOYSA-N n-phenylnitramide Chemical group [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 description 2
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 150000005839 radical cations Chemical class 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 238000003026 viability measurement method Methods 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- BOCBOJPUWMTAJB-UHFFFAOYSA-N (2-butylphenyl) 2-hydroxybenzoate Chemical compound CCCCC1=CC=CC=C1OC(=O)C1=CC=CC=C1O BOCBOJPUWMTAJB-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- VIYKYVYAKVNDPS-HKGPVOKGSA-N (2s)-2-azanyl-3-[3,4-bis(oxidanyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 VIYKYVYAKVNDPS-HKGPVOKGSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 description 1
- KVJHGPAAOUGYJX-UHFFFAOYSA-N 1,1,3,3-tetraethoxypropane Chemical compound CCOC(OCC)CC(OCC)OCC KVJHGPAAOUGYJX-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 1
- DHGBAFGZLVRESL-UHFFFAOYSA-N 14-methylpentadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C DHGBAFGZLVRESL-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- PYJQLUORHGLSGS-UHFFFAOYSA-N 16-methylheptadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC(C)C PYJQLUORHGLSGS-UHFFFAOYSA-N 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- HBXWTSGRLITCMK-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethanol;propane-1,2-diol Chemical compound CC(O)CO.OCCOCCO HBXWTSGRLITCMK-UHFFFAOYSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- ZMXUPLNMYABPEB-UHFFFAOYSA-N 2-[[2-(dodecanoylamino)acetyl]amino]acetic acid Chemical compound CCCCCCCCCCCC(=O)NCC(=O)NCC(O)=O ZMXUPLNMYABPEB-UHFFFAOYSA-N 0.000 description 1
- AKVBCGQVQXPRLD-UHFFFAOYSA-N 2-aminooctanoic acid Chemical compound CCCCCCC(N)C(O)=O AKVBCGQVQXPRLD-UHFFFAOYSA-N 0.000 description 1
- MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical compound ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 description 1
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 description 1
- QSRHBXMVAHNFKV-UHFFFAOYSA-N 2-decyldodecanoic acid Chemical compound CCCCCCCCCCC(C(O)=O)CCCCCCCCCC QSRHBXMVAHNFKV-UHFFFAOYSA-N 0.000 description 1
- OSJVRHJQUTTZIN-UHFFFAOYSA-N 2-ethoxyethyl 2-methoxy-3-phenylprop-2-enoate Chemical compound CCOCCOC(=O)C(OC)=CC1=CC=CC=C1 OSJVRHJQUTTZIN-UHFFFAOYSA-N 0.000 description 1
- GLCFQKXOQDQJFZ-UHFFFAOYSA-N 2-ethylhexyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(CC)CCCC GLCFQKXOQDQJFZ-UHFFFAOYSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- HTNFLUQQANUSLR-UHFFFAOYSA-N 2-octanoyloxyethyl octanoate Chemical compound CCCCCCCC(=O)OCCOC(=O)CCCCCCC HTNFLUQQANUSLR-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- SDZHIRPZKXFSBX-UHFFFAOYSA-N 3-(dodecanoylamino)propanoic acid;zinc Chemical compound [Zn].CCCCCCCCCCCC(=O)NCCC(O)=O SDZHIRPZKXFSBX-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- SGNZYJXNUURYCH-UHFFFAOYSA-N 5,6-dihydroxyindole Chemical compound C1=C(O)C(O)=CC2=C1NC=C2 SGNZYJXNUURYCH-UHFFFAOYSA-N 0.000 description 1
- YFTGOBNOJKXZJC-UHFFFAOYSA-N 5,6-dihydroxyindole-2-carboxylic acid Chemical compound OC1=C(O)C=C2NC(C(=O)O)=CC2=C1 YFTGOBNOJKXZJC-UHFFFAOYSA-N 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- WLJYNHBZKOQNNI-UHFFFAOYSA-N 5-(diaminomethylideneamino)-2-[[1-[2-[[4-methyl-2-[[1-[(4-phenyldiazenylphenyl)methoxycarbonyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]pentanoic acid Chemical compound C1CCC(C(=O)NC(CCCN=C(N)N)C(O)=O)N1C(=O)CNC(=O)C(CC(C)C)NC(=O)C1CCCN1C(=O)OCC(C=C1)=CC=C1N=NC1=CC=CC=C1 WLJYNHBZKOQNNI-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- QVNCZVPOUKXBBQ-UHFFFAOYSA-N C(CCCCCCCCCCC)(=O)OCCCCCCCCCCCC.[Ca] Chemical compound C(CCCCCCCCCCC)(=O)OCCCCCCCCCCCC.[Ca] QVNCZVPOUKXBBQ-UHFFFAOYSA-N 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000030523 Catechol oxidase Human genes 0.000 description 1
- 108010031396 Catechol oxidase Proteins 0.000 description 1
- 244000146462 Centella asiatica Species 0.000 description 1
- 235000004032 Centella asiatica Nutrition 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 241000219130 Cucurbita pepo subsp. pepo Species 0.000 description 1
- 235000003954 Cucurbita pepo var melopepo Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000018783 Dacrycarpus dacrydioides Nutrition 0.000 description 1
- RDOFJDLLWVCMRU-UHFFFAOYSA-N Diisobutyl adipate Chemical compound CC(C)COC(=O)CCCCC(=O)OCC(C)C RDOFJDLLWVCMRU-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- PYVHTIWHNXTVPF-UHFFFAOYSA-N F.F.F.F.C=C Chemical compound F.F.F.F.C=C PYVHTIWHNXTVPF-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 239000004640 Melamine resin Substances 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 108010008364 Melanocortins Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 235000005205 Pinus Nutrition 0.000 description 1
- 241000218602 Pinus <genus> Species 0.000 description 1
- 235000005018 Pinus echinata Nutrition 0.000 description 1
- 235000013264 Pinus jeffreyi Nutrition 0.000 description 1
- 235000016013 Pinus leiophylla var chihuahuana Nutrition 0.000 description 1
- 235000008578 Pinus strobus Nutrition 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- NKSOSPOXQKNIKJ-CLFAGFIQSA-N Polyoxyethylene dioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOC(=O)CCCCCCC\C=C/CCCCCCCC NKSOSPOXQKNIKJ-CLFAGFIQSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000011842 Serrate-Jagged Proteins Human genes 0.000 description 1
- 108010036039 Serrate-Jagged Proteins Proteins 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 239000001744 Sodium fumarate Substances 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010064127 Solar lentigo Diseases 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JBBRZDLNVILTDL-XNTGVSEISA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 16-methylheptadecanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCC(C)C)C1 JBBRZDLNVILTDL-XNTGVSEISA-N 0.000 description 1
- SVRHJWALMLOXMI-UHFFFAOYSA-N [2-(dihydroxymethoxy)phenyl]-phenylmethanone;sodium Chemical compound [Na].OC(O)OC1=CC=CC=C1C(=O)C1=CC=CC=C1 SVRHJWALMLOXMI-UHFFFAOYSA-N 0.000 description 1
- KSHPUQQHKKJVIO-UHFFFAOYSA-N [Na].[Zn] Chemical compound [Na].[Zn] KSHPUQQHKKJVIO-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 1
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 1
- 229940022757 asiaticoside Drugs 0.000 description 1
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- HGKOWIQVWAQWDS-UHFFFAOYSA-N bis(16-methylheptadecyl) 2-hydroxybutanedioate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CC(O)C(=O)OCCCCCCCCCCCCCCCC(C)C HGKOWIQVWAQWDS-UHFFFAOYSA-N 0.000 description 1
- WMNULTDOANGXRT-UHFFFAOYSA-N bis(2-ethylhexyl) butanedioate Chemical compound CCCCC(CC)COC(=O)CCC(=O)OCC(CC)CCCC WMNULTDOANGXRT-UHFFFAOYSA-N 0.000 description 1
- 229940073609 bismuth oxychloride Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- DHAZIUXMHRHVMP-UHFFFAOYSA-N butyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCC DHAZIUXMHRHVMP-UHFFFAOYSA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- AGNCRIYGRWNVIF-UHFFFAOYSA-N calcium;2-(dodecanoylamino)acetic acid Chemical compound [Ca].CCCCCCCCCCCC(=O)NCC(O)=O AGNCRIYGRWNVIF-UHFFFAOYSA-N 0.000 description 1
- CEGYXKLZALIAEI-UHFFFAOYSA-N calcium;2-(dodecanoylamino)ethanesulfonic acid Chemical compound [Ca].CCCCCCCCCCCC(=O)NCCS(O)(=O)=O CEGYXKLZALIAEI-UHFFFAOYSA-N 0.000 description 1
- YEFORLIOCBRMFS-UHFFFAOYSA-N calcium;2-(hexadecanoylamino)ethanesulfonic acid Chemical compound [Ca].CCCCCCCCCCCCCCCC(=O)NCCS(O)(=O)=O YEFORLIOCBRMFS-UHFFFAOYSA-N 0.000 description 1
- HOQGRRFKKLWWOO-UHFFFAOYSA-N calcium;3-(dodecanoylamino)propanoic acid Chemical compound [Ca].CCCCCCCCCCCC(=O)NCCC(O)=O HOQGRRFKKLWWOO-UHFFFAOYSA-N 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940048851 cetyl ricinoleate Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 229940073724 cholesteryl isostearate Drugs 0.000 description 1
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940028356 diethylene glycol monobutyl ether Drugs 0.000 description 1
- 229940031769 diisobutyl adipate Drugs 0.000 description 1
- 229940031569 diisopropyl sebacate Drugs 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 1
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000004664 distearyldimethylammonium chloride (DHTDMAC) Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- CDIPRYKTRRRSEM-UHFFFAOYSA-M docosyl(trimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)C CDIPRYKTRRRSEM-UHFFFAOYSA-M 0.000 description 1
- 108010051081 dopachrome isomerase Proteins 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- XAMHKORMKJIEFW-AYTKPMRMSA-N hexadecyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/C[C@H](O)CCCCCC XAMHKORMKJIEFW-AYTKPMRMSA-N 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- FPMPNVIMFPEKRN-UHFFFAOYSA-N hexyl 16-methylheptadecanoate Chemical compound CCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C FPMPNVIMFPEKRN-UHFFFAOYSA-N 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 229960004881 homosalate Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 150000002462 imidazolines Chemical class 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940093629 isopropyl isostearate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940089456 isopropyl stearate Drugs 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000013490 limbo Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000002865 melanocortin Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- LAQFLZHBVPULPL-UHFFFAOYSA-N methyl(phenyl)silicon Chemical compound C[Si]C1=CC=CC=C1 LAQFLZHBVPULPL-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- NNSWOABHNWRKDR-UHFFFAOYSA-N n',n'-diethylethane-1,2-diamine;octadecanoic acid Chemical compound CCN(CC)CCN.CCCCCCCCCCCCCCCCCC(O)=O NNSWOABHNWRKDR-UHFFFAOYSA-N 0.000 description 1
- RVRFYZGKUZFYAH-UHFFFAOYSA-N n',n'-dimethylpropane-1,3-diamine;octadecanoic acid Chemical compound CN(C)CCCN.CCCCCCCCCCCCCCCCCC(O)=O RVRFYZGKUZFYAH-UHFFFAOYSA-N 0.000 description 1
- VAMFXQBUQXONLZ-UHFFFAOYSA-N n-alpha-eicosene Natural products CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 1
- GQEZCXVZFLOKMC-UHFFFAOYSA-N n-alpha-hexadecene Natural products CCCCCCCCCCCCCCC=C GQEZCXVZFLOKMC-UHFFFAOYSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000019488 nut oil Nutrition 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- PIUVNPNBPWVVKZ-UHFFFAOYSA-N octadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC PIUVNPNBPWVVKZ-UHFFFAOYSA-N 0.000 description 1
- NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- XOEUGELJHSUYGP-UHFFFAOYSA-N octyl 4-aminobenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=C(N)C=C1 XOEUGELJHSUYGP-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- BWOROQSFKKODDR-UHFFFAOYSA-N oxobismuth;hydrochloride Chemical compound Cl.[Bi]=O BWOROQSFKKODDR-UHFFFAOYSA-N 0.000 description 1
- JCGNDDUYTRNOFT-UHFFFAOYSA-N oxolane-2,4-dione Chemical compound O=C1COC(=O)C1 JCGNDDUYTRNOFT-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- VKYWCHMXHQTCJQ-UHFFFAOYSA-N pentyl 4-aminobenzoate Chemical compound CCCCCOC(=O)C1=CC=C(N)C=C1 VKYWCHMXHQTCJQ-UHFFFAOYSA-N 0.000 description 1
- 239000010702 perfluoropolyether Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- LYKRPDCJKSXAHS-UHFFFAOYSA-N phenyl-(2,3,4,5-tetrahydroxyphenyl)methanone Chemical compound OC1=C(O)C(O)=CC(C(=O)C=2C=CC=CC=2)=C1O LYKRPDCJKSXAHS-UHFFFAOYSA-N 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920005668 polycarbonate resin Polymers 0.000 description 1
- 239000004431 polycarbonate resin Substances 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000037333 procollagen synthesis Effects 0.000 description 1
- XATKDVHSLQMHSY-RMKNXTFCSA-N propan-2-yl (e)-3-(4-methoxyphenyl)prop-2-enoate Chemical compound COC1=CC=C(\C=C\C(=O)OC(C)C)C=C1 XATKDVHSLQMHSY-RMKNXTFCSA-N 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229940116422 propylene glycol dicaprate Drugs 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000010499 rapseed oil Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 229940005573 sodium fumarate Drugs 0.000 description 1
- 235000019294 sodium fumarate Nutrition 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 229940117986 sulfobetaine Drugs 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- ZTUXEFFFLOVXQE-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCC(O)=O ZTUXEFFFLOVXQE-UHFFFAOYSA-N 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- SZEMGTQCPRNXEG-UHFFFAOYSA-M trimethyl(octadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C SZEMGTQCPRNXEG-UHFFFAOYSA-M 0.000 description 1
- APVVRLGIFCYZHJ-UHFFFAOYSA-N trioctyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CCCCCCCCOC(=O)CC(O)(C(=O)OCCCCCCCC)CC(=O)OCCCCCCCC APVVRLGIFCYZHJ-UHFFFAOYSA-N 0.000 description 1
- COXJMKGEQAWXNP-UHFFFAOYSA-N tris(14-methylpentadecyl) 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CC(C)CCCCCCCCCCCCCOC(=O)CC(O)(C(=O)OCCCCCCCCCCCCCC(C)C)CC(=O)OCCCCCCCCCCCCCC(C)C COXJMKGEQAWXNP-UHFFFAOYSA-N 0.000 description 1
- AGBVGLJAIGBYAD-UHFFFAOYSA-N tris(2-methylpropyl) 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CC(C)COC(=O)CC(O)(C(=O)OCC(C)C)CC(=O)OCC(C)C AGBVGLJAIGBYAD-UHFFFAOYSA-N 0.000 description 1
- RHNXTZDKMRCKKT-UHFFFAOYSA-N tris(6-methylheptyl) 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CC(C)CCCCCOC(=O)CC(O)(C(=O)OCCCCCC(C)C)CC(=O)OCCCCCC(C)C RHNXTZDKMRCKKT-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Abstract
Description
본 발명은 잣외종피 추출물을 유효성분으로 포함하는 화장료 조성물 및 이를 포함하는 피부 외용제에 관한 것이다.The present invention relates to a cosmetic composition comprising an extract of Pine nut Extract as an active ingredient and a skin external preparation containing the same.
또한 본 발명은 잣외종피 추출물을 유효성분으로 포함하는 식품 조성물 및 약학적 조성물에 관한 것이다. The present invention also relates to a food composition and a pharmaceutical composition comprising an extract of Pine nut Extract as an active ingredient.
최근 웰빙 문화가 트렌드로 대두됨에 따라, 인체건강이나 피부건강에 대한 인식이 증대되면서 자외선, 음식, 환경 등에 의해 야기되는 피부 문제를 개선시키기 위한 목적으로 화장품과 식품, 의약품 등 다양한 분야에서 연구가 활발하게 진행되고 있다. As well-being culture has become a trend in recent years, research on various fields such as cosmetics, foods, and pharmaceuticals has been actively carried out with the aim of improving the skin problems caused by ultraviolet rays, food, environment, etc., .
신체의 최외각층의 보호막으로서의 피부는 자외선과 유해물질 등의 외부 환경으로부터 내부기관을 보호하고 수분과 전해질의 손실을 막는 기능을 하는 기관으로서 외부환경에 항상 노출되어 있어 과도한 자외선 노출은 피부화상, 색소(melanin) 침착, 주름 및 광노화 촉진, 피부염증, 심한 경우 피부암을 일으키는 요인이 되기도 한다. As a protective film of the outermost layers of the body, the skin protects the internal organs from the external environment such as ultraviolet rays and harmful substances, and functions to prevent the loss of water and electrolytes. The skin is always exposed to the external environment. Excessive ultraviolet exposure causes skin burns, melanin deposition, wrinkling and promoting photoaging, skin inflammation, and, in severe cases, skin cancer.
일반적으로 멜라닌(melanin)은 자외선과 같은 외부자극요인으로부터 피부를 보호하기 위해 만들어 진다. 피부에 멜라닌 색소가 과다 침착되면 원하지 않는 주근깨, 노인성 반점, 간반, 기미, 갈색 또는 흑점, 일광 색 소반, 찰상 및 화상을 비롯한 상처 또는 피부염으로 인한 염증 후 과색소침착, 광독성 반응 또는 다른 유사한 소형의 고정 색소성 병변을 일으킬 수 있다.
In general, melanin is made to protect the skin from external stimuli such as ultraviolet light. Over-deposition of melanin pigment on skin may result in hyperpigmentation, phototoxic response or other similar small-sized post-inflammatory reactions due to scarring or dermatitis, including unwanted freckles, senile spots, liver, spots, brown or black spots, It can cause fixed pigmented lesions.
멜라닌 생성은 티로시나아제 tyrosinase), TRP-1 tyrosinase related protein-1), TRP-2의 세 효소에 의해 조절 된다. Melanin의 생합성 기전은 출발물질인 멜라닌의 생합성 기전은 출발물질인 티로신이 rate-limiting enzyme인 티로시나아제 tyrosinase)에 의해 DOPA(3,4-dihydroxyphenylalanin)과 DOPA 퀴논으로 변형되고, DOPA 크롬을 거쳐 중간체인 5,6-dihydroxyindole-2-carboxylic acid로 산화되어 유멜라닌(eumelanin)을 생성하게 된다. 또한 자외선에 의해 피부의 케라티노사이트(keratinocyte)가 자극을 받으면 α-MSH(α-melanocyte sitmulating hormone), ACTH(adrenocorricotropic hormone) 등의 신호전달물질이 멜라노사이트(melanocyte)로 분비하게 된다. 멜라노사이트의 MC1R(melanocortin type 1 receptor) 수용체에서는 이러한 자극을 받아들여 세포내 cAMP(cyclic adenosine monophosphate) 수준을 증가시키며, cAMP의 증가는 PKA(protein kinase A)의 활성화를 일으키고, 뒤이어 CREB(cAMP response element-binding protein)의 인산화를 증가시킨다. 인산화된 CREB는 멜라노사이트의 특정 전사인자인 MITF(microphthalmia associated transcrpition factor)의 MITF의 발현을 일으키게 된다. MITF의 발현은 결국 멜라닌 생성의 주요 효소인 티로시나아제, TRP-1, TRP-2의 프로모터 와의 결합이 촉진되어 멜라닌 생합성이 증가되게 된다. Melanogenesis is regulated by three enzymes, tyrosinase, TRP-1 tyrosinase related protein-1 and TRP-2. The mechanism of biosynthesis of melanin is transformed into DOPA (3,4-dihydroxyphenylalanine) and DOPA quinone by the tyrosinase tyrosinase, which is the starting material, tyrosine, a rate-limiting enzyme, and DOPA chromium is used as the starting material for the biosynthesis of melanin. (5,6-dihydroxyindole-2-carboxylic acid) to produce eumelanin. When keratinocytes in the skin are stimulated by ultraviolet rays, signaling substances such as α-MSH (α-melanocyte-sitmulating hormone) and ACTH (adrenocorricotropic hormone) are secreted into melanocytes.
피부에 노출되는 자외선이 증가함에 따라 여러 단백질 분해효소 중에서 기질을 분해하는 MMPs(matrix metalloproteinase)는 피부 광노화 발생에 중요한 역할을 한다. 피부 진피 내 세포 외 기질단백질(extracellular matrix)은 피부의 구조와 탄력성을 유지하는데 중요한 역할을 하는데, 그 중 80∼85%가 type Ⅰ procollagen으로 이루어져 있다. Type Ⅰ procollagen은 전구체인 procollagen 형태로 합성이 된 후 세포 밖으로 배출되어 아미노 말단과 카복실말단이 잘려나간 후 완성된 collagen을 만들게 된다. 피부 진피 내 세포 외 기질 단백질의 재구성에는 여러 생체 반응이 관하며, 이중 특히 MMPs가 기질 단백질들을 분해하는 중요한 역할을 하고 있으며 intestitial collagenase(MMP-1), 72kD gelatinase(MMP-2), 92kD gelatinase(MMP-9), neutrophil collagenase(MMP-8), collagenase(MMP-13) 등 26가지 이상의 MMPs가 이미 알려져 있다. 자외선에 노출된 피부에서는 MMPs의 발현이 증가되며, 증가된 MMPs가 피부를 구성하고 있는 collagen을 분해하여 기질 단백질의 결핍을 초래하게 됨으로써 피부노화와 주름의 발생이 일어난다. MMPs (matrix metalloproteinase), which degrades substrates among various proteolytic enzymes, play an important role in the development of skin photo-aging as the ultraviolet rays exposed to the skin increase. Extracellular matrix proteins in the dermis play an important role in maintaining the structure and resilience of the skin, 80% to 85% of which is composed of type Ⅰ procollagen. Type I procollagen is synthesized in the form of procollagen, which is a precursor, and then released out of the cell, resulting in a complete collagen after the amino and carboxyl ends are cleaved. In particular, MMPs play an important role in the degradation of matrix proteins, including intestitial collagenase (MMP-1), 72 kD gelatinase (MMP-2), 92 kD gelatinase (MMP-9), neutrophil collagenase (MMP-8), and collagenase (MMP-13) In skin exposed to ultraviolet light, the expression of MMPs is increased, and the increased MMPs break down the collagen that constitutes the skin, resulting in the deficiency of the substrate protein, resulting in skin aging and wrinkles.
잣나무(Pinus koraiensis Siebold et Zucc)는 소나무과에 속하는 상록교목이다. 해발고도 1,000 m 이상에서 자라며 높이 30 m, 지름 1 m 정도까지 자라는 나무로 수피는 회갈색이고 ?은 조각이 떨어진다. 잎은 짧은 가지 끝에 3~5개씩 달리며, 뒷면에는 하얀 기공선이 있어 연한 초록색을 띠고, 가장자리에 잔 톱니가 있다. Pinus pinus koraiensis Siebold et Zucc) is an evergreen tree belonging to the pine tree family. It grows at an elevation of 1,000 m above sea level and grows up to 30 m in height and 1 m in diameter. The bark is gray-brown and the sculpture falls. The leaves are 3 ~ 5 at the end of the short branch, and there is a white pore line on the back, light green color, with serrate on the edge.
잣나무는 전통적으로 구과인 잣을 제외한 나머지 부분은 폐기 자원으로 분류되고 있다. 특히, 잣부산물 증 잣열매인 구과의 경우 껍질(구과 실편)을 제거해야만 외종피에 둘러싸인 황잣(종자)을 수확할 수 있고, 황잣(종자)으로부터 외종피를 제거한 백잣(배유)은 식용으로 활용하고 제거된 껍질(구과 실편 및 외종피)은 그대로 방치되거나 버려지고 있기 때문에 효과적인 활용 방법에 대한 연구가 필요한 실정이다.Traditionally, pine wood has been classified as a waste resource except for pine nuts. In particular, in the case of the cones which are the pine nut of the pine by-product, the husks (seeds) enclosed in the outer husks can be harvested only by removing the shells (outer shells), and the white nuts (endosperm) (Shells and outermost shells) are left untouched or discarded. Therefore, it is necessary to study the effective utilization methods.
이에, 본 발명자들은 잣구과로 부터 백잣(배유)을 수확하기 위해 벗겨진 후 활용되지 않고 버려지는 임산폐자원인 잣구과 껍질(구과 실편 및 외종피) 추출물에서 미백 및 주름개선효과를 가지는 물질이 있음을 확인하고, 본 발명을 완성하기에 이르렀다.
Accordingly, the present inventors have found that there is a substance having an effect of whitening and wrinkle-removing in extracts of zygote and shell (zucchini and exocytosis), which are abandoned after being stripped for harvesting white nuts And have completed the present invention.
본 발명의 일 양상은 잣외종피 추출물을 유효성분으로 포함하는 화장료 조성물 및 이를 포함하는 피부 외용제를 제공하는 것이다.An aspect of the present invention is to provide a cosmetic composition comprising an extract of P. japonicus as an active ingredient and a skin external preparation containing the same.
본 발명의 다른 양상은 잣외종피 추출물을 유효성분으로 포함하는 식품 조성물 및 약학적 조성물을 제공하는 것이다.
Another aspect of the present invention is to provide a food composition and a pharmaceutical composition comprising an extract of P. japonicus as an active ingredient.
본 발명의 일 양상은 잣외종피 추출물을 유효성분으로 포함하는 화장료 조성물을 제공한다.
An aspect of the present invention provides a cosmetic composition comprising an extract of Pine nut Extract as an active ingredient.
이하 본 발명에 대하여 자세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 상기 잣은 잣나무의 열매로서 잣나무(Pinus koraiensis Siebold et Zucc)란 소나무과에 속하는 상록교목이다. 본 발명에서 잣외종피란 잣 송이에서 외종피에 둘러싸인 황잣으로부터 백잣(배유)를 제거하고 남은 종피를 의미한다. The pine nuts of the present invention is pine (Pinus as fruit of pine koraiensis Siebold et Zucc) is an evergreen tree belonging to the pine tree family. In the present invention, the exocrine pine nut refers to the remaining seed after removing the white pine (endosperm) from the yellow pine surrounded by the outer pine in the pine nut.
상기 잣외종피는 성숙한 잣의 외종피일 수 있다. The exotoxin of the pine nut may be an exogenous patch of mature pine nut.
본 발명의 상기 잣외종피 추출물은 물, C1 내지 C4의 저급 알코올 또는 이들의 혼합용매로 추출한 것일 수 있다. 본 발명의 구체예에서는 열수 및 에탄올을 이용하여 추출하였다. 상기 추출물이란 상기 잣외종피의 추출물, 이의 분획물 또는 상기 분획물로부터 분리한 활성분획을 모두 포함하는 개념이다.
The pine nut extract of the present invention may be extracted with water, C1 to C4 lower alcohols or a mixed solvent thereof. In the specific example of the present invention, extraction was performed using hot water and ethanol. The above-mentioned extract is a concept that includes the extract of the pine nut, its fraction or the active fraction isolated from the fraction.
본 발명의 상기 잣외종피 추출물은 항산화, 미백, 모공수축 또는 주름개선용으로 사용될 수 있다. 본 발명의 구체예에서는 잣외종피 추출물의 다양한 유효 활성을 확인하였으며, 구체적으로 상기 잣외종피 추출물은 DPPH, PF, ABTS 및 TBARS를 억제하여 항산화 효과를 가지며, tyrosinase를 저해하고 B16F10세포 실험에서 tyrosine 효소단백질과 MITF 단백질의 발현을 억제함으로써 melanin 생성을 억제하여 미백효과를 나타내었다. 또한 잣외종피 추출물은 esterase 활성을 억제함으로써 elastin분자 형태를 유지시키고, ProCOL1A2를 활성화시키고 MMP-1 및 MMP-9의 발현을 억제함으로써 주름개선 효과를 나타내었다. 따라서 본 발명에 따른 잣외종피 추출물은 항산화, 미백 및 주름개선 효과에 유용한 기능성 원료로 이용 될 수 있다. The pine nut extract of the present invention can be used for antioxidant, whitening, shrinkage of pores or wrinkle improvement. Specifically, the extracts of P. japonica inhibited DPPH, PF, ABTS and TBARS, inhibited tyrosinase, inhibited tyrosine enzyme activity in B16F10 cells, And MITF protein expression to inhibit melanin production and to exhibit a whitening effect. In addition, the extract of P. japonica showed wrinkle-reducing effects by inhibiting esterase activity, maintaining elastin molecular shape, activating ProCOL1A2, and inhibiting the expression of MMP-1 and MMP-9. Therefore, the extract of Pine nut Extract according to the present invention can be used as a functional raw material useful for antioxidative, whitening and wrinkle-reducing effects.
본 발명의 화장료 조성물은 상기 유효성분 이외에 화장료 조성물에 통상적으로 사용되는 항산화제, 안정화제, 용해화제, 비타민, 안료, 향료 등과 같은 통상적인 보조제 및 담체가 더 포함될 수 있다. 예를 들어, 상기 화장료 조성물에는 글리세린, 부틸렌 글라이콜, 폴리옥시에칠렌 경화피마자유, 토코페릴 아세테이트, 시트릭산, 판테놀, 스쿠알란, 소듐 시트레이트, 알란토인 등의 보조성분이 추가로 더 포함될 수 있다.The cosmetic composition of the present invention may further contain conventional auxiliary agents and carriers such as antioxidants, stabilizers, solubilizers, vitamins, pigments, fragrances and the like which are conventionally used in cosmetic compositions, in addition to the above-mentioned effective ingredients. For example, the cosmetic composition may further contain an auxiliary component such as glycerin, butylene glycol, polyoxyethylene hardened castor oil, tocopheryl acetate, citric acid, panthenol, squalane, sodium citrate, allantoin and the like .
상기 잣외종피 추출물은 화장료 조성물 총 중량에 대하여 0.1~50중량%로 포함되며 더욱 바람직하게는 0.3~10중량%로 포함되는 것일 수 있으며 제형, 용도 및 목적에 따라서 함량을 자유롭게 선택할 수 있다.The pine nut extract may be contained in an amount of 0.1 to 50% by weight, more preferably 0.3 to 10% by weight based on the total weight of the cosmetic composition, and may be freely selected depending on the formulation, use and purpose.
예를 들면, 잣 외종피 추출물이 포함된 화장품 1통(30g) 기준으로,For example, on the basis of a single cosmetic product (30 g) containing an extract of Pine nuts,
화장료 조성물 총 중량에 대한Based on the total weight of the cosmetic composition
1) 잣 외종피 추출물 powder 양은, 0.1중량%일 때 0.03g, 0.3중량% 일 때 0.09g, 10중량% 일 때 3g, 50중량%일 때 15g 정도가 들어갈 수 있다.1) The amount of powder of extrudate extract of Pine nuts can be 0.03g at 0.1 wt%, 0.09g at 0.3 wt%, 3g at 10 wt%, and 15g at 50 wt%.
2) Phenolic compounds 양은 0.1% 함유일 때 0.1767mg, 0.3% 함유일 때 0.531mg, 10% 함유일 때 17.67mg, 50% 함유일 때 88.35mg 정도가 함유될 수 있으며, 2) The amount of phenolic compounds may be 0.1767 mg at 0.1% content, 0.531 mg at 0.3% content, 17.67 mg at 10% content, and 88.35 mg at 50% content,
3) 원재료의 중량은 50% 함유일 때 외종피 390g 정도가 사용된다.3) When the weight of raw material is 50%, about 390g of exocytosis is used.
본 발명의 화장료에는 상기 필수 성분과 더불어 필요에 따라 통상 화장료에 배합되는 다른 성분을 배합해도 된다.The cosmetic of the present invention may be blended with other essential ingredients, if necessary, in combination with the essential ingredients.
이외에 첨가해도 되는 배합 성분으로서는 유지 성분, 보습제, 에몰리엔트제, 계면 활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 식물 추출물, pH 조정제, 알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제한(制汗)제, 정제수 등을 들 수 있다.Examples of the compounding ingredients that may be added include organic solvents such as a preservative component, a moisturizer, an emollient, a surfactant, an organic and inorganic pigment, an organic powder, an ultraviolet absorbent, a preservative, a bactericide, an antioxidant, a plant extract, a pH adjuster, A blood circulation accelerator, a cold agent, an antiperspirant agent, and purified water.
유지 성분으로는 에스테르계 유지, 탄화수소계 유지, 실리콘계 유지, 불소계 유지, 동물 유지, 식물 유지 등을 들 수 있다.Examples of the fat-soluble ingredients include ester-based fats, hydrocarbon-based fats, silicon-based fats, fluorine-based fats, animal fats and plant fats and the like.
에스테르계 유지로는 트리2-에틸헥산산글리세릴, 2-에틸헥산산세틸, 미리스틴산이소프로필, 미리스틴산부틸, 팔미틴산이소프로필, 스테아르산에틸, 팔미틴산옥틸, 이소스테아르산이소세틸, 스테아르산부틸, 리놀레산에틸, 리놀레산이소프로필, 올레인산에틸, 미리스틴산이소세틸, 미리스틴산이소스테아릴, 팔미틴산이소스테아릴, 미리스틴산옥틸도데실, 이소스테아르산이소세틸, 세바신산디에틸, 아디핀산디이소프로필, 네오펜탄산이소알킬, 트리(카프릴, 카프린산)글리세릴, 트리2-에틸헥산산트리메틸롤프로판, 트리이소스테아르산트리메틸롤프로판, 테트라2-에틸헥산산펜타엘리슬리톨, 카프릴산세틸, 라우린산데실, 라우린산헥실, 미리스틴산데실, 미리스틴산미리스틸, 미리스틴산세틸, 스테아르산스테아릴, 올레인산데실, 리시노올레인산세틸, 라우린산이소스테아릴, 미리스틴산이소트리데실, 팔미틴산이소세틸, 스테아르산옥틸, 스테아르산이소세틸, 올레인산이소데실, 올레인산옥틸도데실, 리놀레산옥틸도데실, 이소스테아르산이소프로필, 2-에틸헥산산세토스테아릴, 2-에틸헥산산스테아릴, 이소스테아르산헥실, 디옥탄산에틸렌글리콜, 디올레인산에틸렌글리콜, 디카프린산프로필렌글리콜, 디(카프릴,카프린산)프로필렌글리콜, 디카프릴산프로필렌글리콜, 디카프린산네오펜틸글리콜, 디옥탄산네오펜틸글리콜, 트리카프릴산글리세릴, 트리운데실산글리세릴, 트리이소팔미틴산글리세릴, 트리이소스테아르산글리세릴, 네오펜탄산옥틸도데실, 옥탄산이소스테아릴, 이소노난산옥틸, 네오데칸산헥실데실, 네오데칸산옥틸도데실, 이소스테아르산이소세틸, 이소스테아르산이소스테아릴, 이소스테아르산옥틸데실, 폴리글리세린올레인산에스테르, 폴리글리세린이소스테아르산에스테르, 시트르산트리이소세틸, 시트르산트리이소알킬, 시트르산트리이소옥틸, 락트산라우릴, 락트산미리스틸, 락트산세틸, 락트산옥틸데실, 시트르산트리에틸, 시트르산아세틸트리에틸, 시트르산아세틸트리부틸, 시트르산트리옥틸, 말산디이소스테아릴, 히드록시스테아르산 2-에틸헥실, 숙신산디2-에틸헥실, 아디핀산디이소부틸, 세바신산디이소프로필, 세바신산디옥틸, 스테아르산콜레스테릴, 이소스테아르산콜레스테릴, 히드록시스테아르산콜레스테릴, 올레인산콜레스테릴, 올레인산디히드로콜레스테릴, 이소스테아르산피트스테릴, 올레인산피트스테릴, 12-스테알로일히드록시스테아르산이소세틸, 12-스테알로일히드록시스테아르산스테아릴, 12-스테알로일히드록시스테아르산이소스테아릴 등의 에스테르계 등을 들 수 있다.Examples of ester-based fats include glyceryl tri-2-ethylhexanoate, cetyl 2-ethylhexanoate, isopropyl myristate, butyl myristate, isopropyl palmitate, ethyl stearate, octyl palmitate, isocetyl isostearate, But are not limited to, ethylbutyl, butylbutyl, ethylbutylbutyl, butylbutyl, isobutylbutyl, isobutylbutyl, isobutylisobutyl, isobutylisobutyl, isobutylisobutyl, Trimethylol propane, triisostearic acid trimethylol propane, tetra-2-ethylhexanoic acid pentaerythritol tri (2-ethylhexanoic acid) Terephthalic acid, stearic acid, tallow, caprylic acid, decyl lauric acid, hexyl laurate, myristic acid myristate, myristyl myristate, myristyl acid stearyl, stearyl stearate, decyl oleate, cetyl ricinoleate, Octyldodecyl oleate, octyldodecyl oleate, octyldodecyl linoleate, isopropyl isostearate, isopropyl stearate, isostearyl stearate, isocetyl stearate, isodecyl oleate, isodecyl oleate, octyldodecyl oleate, Ethylhexanoate, stearylhexyl isostearate, stearyl 2-ethylhexanoate, hexyl isostearate, ethylene glycol dioctanoate, ethylene glycol dioleate, propylene glycol dicaprate, di (capryl, capric acid) propylene glycol, dicapryl Diethylene glycol monobutyl ether, diethylene glycol propylene glycol, dicapric acid neopentyl glycol, dioctanoic acid neopentyl glycol, tricarboxylic acid glyceryl, triunsaturated glyceryl, triisopalmitic acid glyceryl, triisostearic acid glyceryl, Octanoic acid octanoate, octanoic acid octanoate, octanoic acid octanoate, octanoic acid octanoate, octanoic acid octanoate, octanoic acid octanoate, octanoic acid octanoate, octanoic acid octanoate, octanoic acid octanoate, Octyldecyl lactate, octyldecyl stearate, polyglycerin oleic acid ester, polyglycerin isostearic acid ester, triisocetyl citrate, triisobutyl citrate, triisooctyl citrate, myristyl lactate, cetyl lactate, octyldecyl lactate, triethyl citrate , Acetyl triethyl citrate, acetyl tributyl citrate, trioctyl citrate, diisostearyl malate, 2-ethylhexyl hydroxystearate, di-2-ethylhexyl succinate, diisobutyl adipate, diisopropyl sebacate, Cholesteryl isostearate, chitostearic acid, cholestearyl isostearate, cholestearyl hydroxystearate, cholesteryl oleate, dihydrocholestearyl oleate, pitostearyl isostearate, pitostearyl oleate, 12 -Stearoylhydroxystearic acid isostearyl, 12-stearoylhydroxystearic stearyl, 12-stearoyl And esters such as hydroxystearic acid and sostearyl.
탄화 수소계 유지로는 스쿠알렌, 유동 파라핀, 알파-올레핀올리고머, 이소파라핀, 세레신, 파라핀, 유동 이소파라핀, 폴리부덴, 마이크로크리스탈린왁스, 와셀린 등의 탄화 수소계 유지 등을 들 수 있다.Hydrocarbon-based fats and oils such as squalene, liquid paraffin, alpha-olefin oligomer, isoparaffin, ceresin, paraffin, floating isoparaffin, polybutene, microcrystalline wax, and hydrogenated hydrocarbon such as vaseline.
실리콘계 유지로는 폴리메틸실리콘, 메틸페닐실리콘, 메틸시클로폴리실록산, 옥타메틸폴리실록산, 데카메틸폴리실록산, 도데카메틸시클로실록산, 디메틸실록산ㆍ메틸세틸옥시실록산 공중합체, 디메틸실록산ㆍ메틸스테알록시실록산 공중합체, 알킬 변성 실리콘유, 아미노 변성 실리콘유 등을 들 수 있다.Examples of silicone based oils include polymethyl silicone, methylphenyl silicone, methyl cyclopolysiloxane, octamethylpolysiloxane, decamethylpolysiloxane, dodecamethylcyclosiloxane, dimethylsiloxane-methylcetyloxysiloxane copolymer, dimethylsiloxane-methylstarchoxysiloxane copolymer, Alkyl-modified silicone oil, and amino-modified silicone oil.
불소계 유지로서는 퍼플루오로폴리에테르 등을 들 수 있다.Examples of the fluorine-based oil include perfluoropolyether and the like.
동물 또는 식물 유지로는 아보카도유, 아르몬드유, 올리브유, 참깨유, 쌀겨유, 새플라워유, 대두유, 옥수수유, 유채유, 행인(杏仁)유, 팜핵유, 팜유, 피마자유, 해바라기유, 포도종자유, 면실유, 야자유, 쿠쿠이너트유, 소맥배아유, 쌀 배아유, 시아버터, 월견초유, 마커데이미아너트유, 메도홈유, 난황유, 우지(牛脂), 마유, 밍크유, 오렌지라피유, 호호바유, 캔데리러왁스, 카르나바왁스, 액상 라놀린, 경화피마자유 등의 동물 또는 식물 유지를 들 수 있다.Examples of the animal or vegetable oil include avocado oil, almond oil, olive oil, sesame oil, rice bran oil, new flower oil, soybean oil, corn oil, rape oil, apricot kernel oil, palm kernel oil, palm oil, castor oil, sunflower oil, The present invention relates to a process for producing a starch-containing starch, which is selected from the group consisting of seed oil, cottonseed oil, palm oil, palm oil, cucumber nut oil, wheat germ oil, rice germ oil, Animal or vegetable fats such as oil, can-pick wax, carnauba wax, liquid lanolin, and hardened castor oil.
보습제로서는 수용성 저분자 보습제, 지용성 분자 보습제, 수용성 고분자, 지용성 고분자 등을 들 수 있다.Examples of the moisturizing agent include water-soluble low-molecular moisturizing agents, oil-soluble molecular moisturizing agents, water-soluble polymers, and oil-soluble polymers.
수용성 저분자 보습제로는 세린, 글루타민, 솔비톨, 만니톨, 피롤리돈-카르복실산나트륨, 글리세린, 프로필렌글리콜, 1,3-부틸렌글리콜, 에틸렌글리콜, 폴리에틸렌글리콜B(중합도 n = 2 이상), 폴리프로필렌글리콜(중합도 n = 2 이상), 폴리글리세린B(중합도 n = 2 이상), 락트산, 락트산염 등을 들 수 있다.Examples of the water-soluble low molecular weight moisturizing agent include serine, glutamine, sorbitol, mannitol, sodium pyrrolidone-carboxylate, glycerin, propylene glycol, 1,3-butylene glycol, ethylene glycol, polyethylene glycol B Propylene glycol (polymerization degree n = 2 or more), polyglycerin B (polymerization degree n = 2 or more), lactic acid, lactic acid salt and the like.
지용성 저분자 보습제로는 콜레스테롤, 콜레스테롤에스테르 등을 들 수 있다.Examples of the lipid-soluble low-molecular moisturizing agent include cholesterol and cholesterol ester.
수용성 고분자로는 카르복시비닐폴리머, 폴리아스파라긴산염, 트라가칸트, 크산탄검, 메틸셀룰로오스, 히드록시메틸셀룰로오스, 히드록시에틸셀룰로오스, 히드록시프로필셀룰로오스, 카르복시메틸셀룰로오스, 수용성 키틴, 키토산, 덱스트린 등을 들 수 있다.Examples of the water-soluble polymer include carboxyvinyl polymer, polyaspartic acid, tragacanth, xanthan gum, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, water-soluble chitin, chitosan, .
지용성 고분자로는 폴리비닐피롤리돈ㆍ에이코센 공중합체, 폴리비닐피롤리돈ㆍ헥사데센 공중합체, 니트로셀룰로오스, 덱스트린지방산에스테르, 고분자 실리콘 등을 들 수 있다.Examples of the oil-soluble polymer include a polyvinylpyrrolidone / eicosene copolymer, a polyvinylpyrrolidone / hexadecene copolymer, a nitrocellulose, a dextrin fatty acid ester, and a polymeric silicone.
에몰리엔트제로서는 장쇄아실글루타민산콜레스테릴에스테르, 히드록시스테아르산콜레스테릴, 12-히드록시스테아르산, 스테아르산, 로진산, 라놀린지방산콜레스테릴에스테르 등을 들 수 있다.Examples of the emollients include long chain acyl glutamic acid cholesteryl ester, hydroxystearic acid cholesteryl, 12-hydroxystearic acid, stearic acid, rosin acid and lanolin fatty acid cholesteryl ester.
계면 활성제로는 비이온성 계면 활성제, 음이온성 계면 활성제, 양이온성 계면 활성제, 양성 계면 활성제 등을 들 수 있다.Examples of the surfactant include a nonionic surfactant, an anionic surfactant, a cationic surfactant, and a positive surfactant.
비이온성 계면 활성제로는 자기 유화형 모노스테아르산글리세린, 프로필렌글리콜지방산에스테르, 글리세린지방산에스테르, 폴리글리세린지방산에스테르, 솔비탄지방산에스테르, POE (폴리옥시에틸렌)솔비탄지방산에스테르, POE 솔비트지방산에스테르, POE 글리세린지방산에스테르, POE 알킬에테르, POE 지방산에스테르, POE 경화피마자유, POE 피마자유, POEㆍPOP (폴리옥시에틸렌ㆍ폴리옥시프로필렌) 공중합체, POEㆍPOP 알킬에테르, 폴리에테르변성실리콘, 라우린산알카놀아미드, 알킬아민옥시드, 수소첨가대두인지질 등을 들 수 있다.Examples of nonionic surfactants include self emulsifying monostearic acid glycerin, propylene glycol fatty acid esters, glycerin fatty acid esters, polyglycerin fatty acid esters, sorbitan fatty acid esters, POE (polyoxyethylene) sorbitan fatty acid esters, POE sorbit fatty acid esters, POE-POP fatty acid ester, POE alkyl ether, POE fatty acid ester, POE hardened castor oil, POE castor oil, POE.POP (polyoxyethylene.polyoxypropylene) copolymer, POE.POP alkyl ether, polyether- Acid alkanolamides, alkylamine oxides, hydrogenated soybean phospholipids, and the like.
음이온성 계면 활성제로는 지방산비누, 알파-아실술폰산염, 알킬술폰산염, 알킬알릴술폰산염, 알킬나프탈렌술폰산염, 알킬황산염, POE 알킬에테르황산염, 알킬아미드황산염, 알킬인산염, POE 알킬인산염, 알킬아미드인산염, 알킬로일알킬타우린염, N-아실아미노산염, POE 알킬에테르카르복실산염, 알킬술포숙신산염, 알킬술포아세트산나트륨, 아실화 가수분해 콜라겐펩티드염, 퍼플루오로알킬인산에스테르 등을 들 수 있다.Examples of the anionic surfactant include fatty acid soap, alpha-acylsulfonate, alkylsulfonate, alkylallylsulfonate, alkylnaphthalenesulfonate, alkylsulfate, POE alkyl ether sulfate, alkylamide sulfate, alkyl phosphate, POE alkyl phosphate, Alkylsulfosuccinic acid salts, acylated hydrolyzed collagen peptide salts, and perfluoroalkyl phosphoric acid esters, and the like can be mentioned. have.
양이온성 계면 활성제로는 염화알킬트리메틸암모늄, 염화스테아릴트리메틸암모늄, 브롬화스테아릴트리메틸암모늄, 염화세토스테아릴트리메틸암모늄, 염화디스테아릴디메틸암모늄, 염화스테아릴디메틸벤질암모늄, 브롬화베헤닐트리메틸암모늄, 염화벤잘코늄, 스테아르산디에틸아미노에틸아미드, 스테아르산디메틸아미노프로필아미드, 라놀린 유도체 제 4급 암모늄염 등을 들 수 있다.Examples of the cationic surfactant include alkyl trimethyl ammonium chloride, stearyl trimethyl ammonium chloride, stearyl trimethyl ammonium bromide, cetostearyl trimethyl ammonium chloride, distearyl dimethyl ammonium chloride, stearyl dimethyl benzyl ammonium chloride, behenyl trimethyl ammonium bromide, Benzalkonium chloride, diethylaminoethylamide stearate, dimethylaminopropylamide stearate, quaternary ammonium salts of lanolin derivatives, and the like.
양성 계면 활성제로는 카르복시베타인형, 아미드베타인형, 술포베타인형, 히드록시술포베타인형, 아미드술포베타인형, 포스포베타인형, 아미노카르복실산염형, 이미다졸린 유도체형, 아미드아민형 등의 양성 계면 활성제 등을 들 수 있다.Examples of amphoteric surfactants include carboxybetaine, amidebetaine, sulfobetaine, hydroxysulfobetaine, amidosulfobetaine, phosphobetaine, aminocarboxylate, imidazoline derivative, amideamine, etc. , And the like.
유기 및 무기 안료로는 규산, 무수규산, 규산마그네슘, 탤크, 세리사이트, 마이카, 카올린, 벵갈라, 클레이, 벤토나이트, 티탄피막운모, 옥시염화비스무트, 산화지르코늄, 산화마그네슘, 산화아연, 산화티탄, 산화알루미늄, 황산칼슘, 황산바륨, 황산마그네슘, 탄산칼슘, 탄산마그네슘, 산화철, 군청, 산화크롬, 수산화크롬, 칼라민 및 이들의 복합체등의 무기 안료 ; 폴리아미드, 폴리에스테르, 폴리프로필렌, 폴리스티렌, 폴리우레탄, 비닐수지, 요소수지, 페놀수지, 불소수지, 규소수지, 아크릴수지, 멜라민수지, 에폭시수지, 폴리카보네이트수지, 디비닐벤젠ㆍ스티렌 공중합체, 실크파우더, 셀룰로오스, CI 피그먼트옐로우, CI 피그먼트오렌지 등의 유기 안료 및 이들의 무기 안료와 유기 안료의 복합 안료 등을 들 수 있다.Examples of the organic and inorganic pigments include inorganic pigments such as silicic acid, anhydrous silicic acid, magnesium silicate, talc, sericite, mica, kaolin, Bengala, clay, bentonite, titanium mica, titanium oxide mica, bismuth oxychloride, zirconium oxide, Inorganic pigments such as aluminum, calcium sulfate, barium sulfate, magnesium sulfate, calcium carbonate, magnesium carbonate, iron oxide, chromium oxide, chromium oxide, chromium oxide, But are not limited to, polyamide, polyester, polypropylene, polystyrene, polyurethane, vinyl resin, urea resin, phenol resin, fluororesin, silicon resin, acrylic resin, melamine resin, epoxy resin, polycarbonate resin, Silk powder, cellulose, CI Pigment Yellow, CI Pigment Orange, and composite pigments of inorganic pigments and organic pigments thereof.
유기 분체로는 스테아르산칼슘 등의 금속비누; 세틸린산아연나트륨, 라우릴린산아연, 라우릴린산칼슘 등의 알킬인산금속염; N-라우로일-베타-알라닌칼슘, N-라우로일-베타-알라닌아연, N-라우로일글리신칼슘 등의 아실아미노산 다가금속염; N-라우로일-타우린칼슘, N-팔미토일-타우린칼슘 등의 아미드술폰산 다가금속염; N-엡실론-라우로일-L-리진, N-엡실론-팔미토일리진, N-알파-파리토일올니틴, N-알파-라우로일아르기닌, N-알파-경화우지지방산아실아르기닌 등의 N-아실염기성아미노산; N-라우로일글리실글리신 등의 N-아실폴리펩티드; 알파-아미노카프릴산, 알파-아미노라우린산 등의 알파-아미노지방산; 폴리에틸렌, 폴리프로필렌, 나일론, 폴리메틸메타크릴레이트, 폴리스티렌, 디비닐벤젠ㆍ스티렌 공중합체, 사불화에틸렌 등을 들 수 있다.Examples of the organic powder include metal soaps such as calcium stearate; Metal salts of alkyl phosphates such as sodium zinc cetylate, zinc laurylate and calcium lauryl laurate; Acylamino acid polyvalent metal salts such as N-lauroyl-beta-alanine calcium, N-lauroyl-beta-alanine zinc and N-lauroylglycine calcium; Amidosulfonic acid multivalent metal salts such as N-lauroyl-taurine calcium and N-palmitoyl-taurine calcium; Such as N-epsilon-lauroyl-L-lysine, N-epsilon-palmitoylidene, N-alpha-paratyylnitine, N-alpha-lauroyl arginine, Acyl basic amino acids; N-acylpolypeptides such as N-lauroylglycylglycine; Alpha-amino fatty acids such as alpha-aminocaprylic acid, alpha-aminoaurauric acid, and the like; Polyethylene, polypropylene, nylon, polymethylmethacrylate, polystyrene, divinylbenzene-styrene copolymer, ethylene tetrafluoride, and the like.
자외선 흡수제로는 파라아미노벤조산, 파라아미노벤조산에틸, 파라아미노벤조산아밀, 파라아미노벤조산옥틸, 살리실산에틸렌글리콜, 살리신산페닐, 살리신산옥틸, 살리신산벤질, 살리신산부틸페닐, 살리신산호모멘틸, 계피산벤질, 파라메톡시계피산-2-에톡시에틸, 파라메톡시계피산옥틸, 디파라메톡시계피산모노-2-에틸헥산글리세릴, 파라메톡시계피산이소프로필, 디이소프로필ㆍ디이소프로필계피산에스테르 혼합물, 우로카닌산, 우로카닌산에틸, 히드록시메톡시벤조페논, 히드록시메톡시벤조페논술폰산 및 그 염, 디히드록시메톡시벤조페논, 디히드록시메톡시벤조페논디술폰산나트륨, 디히드록시벤조페논, 테트라히드록시벤조페논, 4-tert-부틸-4'-메톡시디벤조일메탄, 2,4,6-트리아닐리노-p-(카르보-2'-에틸헥실-1'-옥시)-1,3,5-트리아진, 2-(2-히드록시-5-메틸페닐)벤조트리아졸 등을 들 수 있다.Examples of the ultraviolet absorbing agent include pamoaminobenzoic acid, ethyl p-aminobenzoate, amyl p-aminobenzoate, octyl p-aminobenzoate, ethylene glycol salicylate, phenyl salicinate, benzyl salicylate, benzyl salicylate, butylphenyl salicylate, homomenthyl salicylate, Benzyl, 2-ethoxyethyl methoxycinnamate, octyl methoxycinnamate, mono-2-ethylhexane glyceryl dipyrromethoxycinnamate, isopropyl methoxycinnamate, diisopropyl-diisopropyl cinnamate ester mixture, Dihydroxymethoxybenzophenone sulfonic acid, dihydroxybenzophenone sulfonic acid, dihydroxybenzophenone sulfonic acid and its salt, dihydroxymethoxybenzophenone, sodium dihydroxymethoxybenzophenone disulfonate, dihydroxybenzo Phenanone, tetrahydroxybenzophenone, 4- tert -butyl-4'-methoxydibenzoylmethane, 2,4,6-trianylino- p- (carbo-2'-ethylhexyl- 1,3,5-triazine, 2- (2- When the like can be mentioned 5-methylphenyl) benzotriazole.
살균제로는 히노키티올, 트리클로산, 트리클로로히드록시디페닐에테르, 크로르헥시딘글루콘산염, 페녹시에탄올, 레조르신, 이소프로필메틸페놀, 아줄렌, 살리칠산, 진크필리티온, 염화벤잘코늄, 감광소 301 호, 모노니트로과이어콜나트륨, 운데시렌산 등을 들 수 있다.Examples of the bactericide include hinokitiol, trichloroacetic acid, trichlorohydroxydiphenyl ether, crohexidine gluconate, phenoxyethanol, resorcin, isopropylmethylphenol, azulene, salicylic acid, No. 301, mononitro and eicoll sodium, undecylenic acid, and the like.
산화 방지제로는 부틸히드록시아니솔, 갈릭산프로필, 엘리소르빈산 등을 들 수 있다.Examples of the antioxidant include butylhydroxyanisole, gallic acid propyl, and eicosorbic acid.
pH 조정제로는 시트르산, 시트르산나트륨, 말산, 말산나트륨, 프말산, 프말산나트륨, 숙신산, 숙신산나트륨, 수산화나트륨, 인산일수소나트륨 등을 들 수 있다.Examples of the pH adjusting agent include citric acid, sodium citrate, malic acid, sodium malate, fumaric acid, sodium fumarate, succinic acid, sodium succinate, sodium hydroxide, sodium monohydrogenphosphate and the like.
알코올로는 세틸알코올 등의 고급 알코올을 들 수 있다.Examples of the alcohol include higher alcohols such as cetyl alcohol.
또한, 이외에 첨가해도 되는 배합 성분은 이에 한정되는 것은 아니며, 상기 어느 성분도 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 배합 가능하지만, 총중량에 대하여 바람직하게는 0.01-5% 중량 백분율, 보다 바람직하게는 0.01-3% 중량 백분율로 배합된다.Any of the above components may be blended to the extent that the object and effect of the present invention are not impaired, but is preferably 0.01-5% by weight, more preferably 0.01-5% by weight based on the total weight of the composition Lt; RTI ID = 0.0 >% < / RTI >
본 발명의 화장료는 용액, 유화물, 점성형 혼합물 등의 형상을 취할 수 있다.The cosmetic of the present invention may take the form of a solution, an emulsion, a viscous mixture or the like.
본 발명의 화장료 조성물에 포함되는 성분은 유효성분으로서 상기 추출물 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예를 들면 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제 및 담체를 포함한다.
The ingredients contained in the cosmetic composition of the present invention may contain, in addition to the above extracts, the components commonly used in cosmetic compositions, for example, conventional additives such as stabilizers, solubilizers, vitamins, Carrier.
또한, 본 발명의 일 양상은 상기 잣외종피 추출물을 포함하는 피부 외용제를 제공한다. 상기 외용제는 항산화, 미백, 모공축소 또는 주름개선을 위하여 화장료로서 이용될 수 있으며, 색소 침착 질환의 예방 또는 치료용 약제로서 이용될 수 있다. In addition, one aspect of the present invention provides an external preparation for skin comprising the pine nut extract. The external preparation may be used as a cosmetic for antioxidant, whitening, reduction of pores or wrinkle improvement, and may be used as a medicine for preventing or treating pigmentation diseases.
본 발명의 외용제는 당업계의 공지기술을 참조하여 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있다. 예를 들어, 용액, 현탁액, 유탁액, 유연 화장수, 영양 화장수, 페이스트, 겔, 크림, 로션, 에센스, 에멀전, 팩, 세안제, 겔, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양크림, 마사지크림, 에센스, 아이크림, 클렌징크림, 클렌징폼, 클렌징워터, 마스크팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The external preparation of the present invention can be prepared into any formulation conventionally produced by referring to the known art in the art. For example, the compositions may be formulated as solutions, suspensions, emulsions, suppositories, suppositories, pastes, gels, creams, lotions, essences, emulsions, packs, cleansers, gels, powders, Emulsion foundation, wax foundation and spray, but are not limited thereto. More specifically, it can be manufactured in the form of a soft lotion, a nutritional lotion, a nutritive cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a mask pack, a spray or a powder.
상기 추출물을 피부 외용제로 이용하기 위하여 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 피부용 외용제에 통상적으로 사용되는 임의의 다른 성분과 같은 피부 과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 또한, 상기 성분들은 피부 과학 분야에서 일반적으로 사용되는 양으로 도입될 수 있다.In order to use the extract as an external preparation for skin, it may further comprise at least one selected from the group consisting of fatty substances, organic solvents, solubilizers, thickeners and gelling agents, softening agents, antioxidants, suspending agents, stabilizing agents, foaming agents, Any of those commonly used in emulsifying or emulsifying agents, fillers, sequestering and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, ≪ / RTI > and other ingredients of the skin. In addition, the components can be introduced in amounts commonly used in the dermatology field.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화아연 등이 포함될 수 있다.When the formulation of the present invention is a paste, cream or gel, the carrier component may include an animal oil, vegetable oil, wax, paraffin, starch, tracer, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, have.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트, 폴리아미드 파우더 등이 포함될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄, 디메틸 에테르 등의 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, the carrier component may include lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder and the like. Particularly in the case of a spray, a mixture of chlorofluorohydrocarbons, propane / Propane, dimethyl ether, and the like.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로 용매, 용해화제, 유탁화제 등이 포함될 수 있고, 구체적으로 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜, 소르비탄의 지방산 에스테르 등이 포함될 수 있다.When the formulation of the present invention is a solution or an emulsion, the carrier component may include a solvent, a solubilizing agent, and an emulsifying agent. Specific examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, fatty acid esters of sorbitan, and the like.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로 물, 에탄올, 프로필렌글리콜 등의 액상 희석제; 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르, 폴리옥시에틸렌 소르비탄 에스테르 등의 현탁제; 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가, 트라칸트 등이 포함될 수 있다.When the formulation of the present invention is a suspension, a liquid diluent such as water, ethanol, propylene glycol or the like as a carrier component; Suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester; Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, trachant, and the like.
본 발명의 제형이 계면활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성유, 라놀린유도체, 에톡실화 글리세롤 지방산 에스테르 등이 포함될 수 있다.
When the formulation of the present invention is a surfactant-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide ether Aliphatic alcohols, fatty acid glycerides, fatty acid diethanol amides, vegetable oils, lanolin derivatives, ethoxylated glycerol fatty acid esters, and the like.
또한, 본 발명의 일 양상은 잣외종피 추출물을 유효성분으로 포함하는 항산화, 미백 또는 노화방지용 식품 조성물을 제공한다. Further, one aspect of the present invention provides a food composition for antioxidant, whitening or antioxidation comprising an extract of Pine Pine Nutrient Extract as an active ingredient.
본 발명의 추출물이 식품 첨가물로 사용할 경우, 상기 추출물을 그대로 첨가하거나, 다른 식품 또는 식품 성분과 함께 혼합하여 사용되는 등 통상적인 방법에 따라 적절하게 사용될 수 있다. When the extract of the present invention is used as a food additive, it can be suitably used according to a conventional method such as adding the extract as it is, mixing it with another food or food ingredient, and the like.
또한 상기 유효성분인 추출물의 혼합양은 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 변경될 수 있음은 물론이며, 상기 추출물은 식품 조성물 총 중량에 대하여 0.001~50 중량%로 포함되는 것이 바람직하고, 더욱 바람직하게는 0.1~30중량%로 포함되는 것이다. The amount of the extract as the active ingredient may be suitably changed according to the purpose of use (prevention, health or therapeutic treatment), and the extract may be contained in an amount of 0.001 to 50% by weight based on the total weight of the food composition By weight, more preferably 0.1 to 30% by weight.
구체적인 예로, 식품 또는 음료의 제조 시에는 본 발명의 추출물은 원료에 대하여 30 중량% 이하, 바람직하게는 10 중량% 이하의 양으로 첨가되는 것이다. 그러나 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하여 장기간 섭취할 경우에는 상기 범위 이하의 양으로 첨가될 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다. As a specific example, the extract of the present invention is added in an amount of not more than 30% by weight, preferably not more than 10% by weight based on the raw material. However, when it is intended for health and hygiene purposes or for the purpose of controlling health, it can be added in an amount below the above range, and there is no problem in terms of safety. Therefore, the active ingredient may be used in an amount exceeding the above range have.
상기 식품의 종류에 특별한 제한은 없다. 본 발명의 추출물을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 수프, 음료수, 차, 드링크제, 알코올 음료, 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of the food. Examples of the food to which the extract of the present invention can be added include meat products, sausages, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, Drinks, alcoholic beverages, vitamin complexes, and the like, all of which include health foods in a conventional sense.
본 발명의 식품 조성물이 음료로 제조될 경우 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등의 추가 성분을 포함할 수 있다. 상기 천연 탄수화물로는 포도당, 과당 등의 모노사카라이드; 말토오스, 수크로오스 등의 디사카라이드; 덱스트린, 사이클로덱스트린 등의 천연 감미제나 사카린, 아스파르탐 등의 합성 감미제 등이 사용될 수 있다. 상기 천연 탄수화물은 본 발명의 식품 조성물 총 중량에 대하여 0.01~10중량%, 바람직하게는 0.01~0.1중량%로 포함되는 것이다.When the food composition of the present invention is prepared as a beverage, it may contain additional ingredients such as various flavors or natural carbohydrates such as ordinary beverages. Examples of the natural carbohydrate include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Natural sweeteners such as dextrin and cyclodextrin, synthetic sweeteners such as saccharin and aspartame, and the like. The natural carbohydrate is contained in an amount of 0.01 to 10% by weight, preferably 0.01 to 0.1% by weight based on the total weight of the food composition of the present invention.
상기 외에 본 발명의 식품 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 포함할 수 있다. 뿐만 아니라, 본 발명의 조성물은 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 포함할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 상기의 첨가제 비율은 크게 제한되지는 않으나, 본 발명의 식품 조성물 총 중량에 대하여 0.01~0.1중량% 범위내로 포함되는 것이 좋다.
In addition to the above, the food composition of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, , Carbonating agents used in carbonated beverages, and the like. In addition, the compositions of the present invention may include flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of the above additives is not limited to a great extent, but may be in the range of 0.01 to 0.1% by weight based on the total weight of the food composition of the present invention.
또한, 본 발명의 일 양상은 잣외종피 추출물을 유효성분으로 포함하는 색소 침착 질환의 치료 또는 예방용 약학적 조성물을 제공한다. 상기 색소 침착 질환은 주근깨, 노인성 반점, 간반, 기미, 갈점, 흑점, 일광 색소반, 푸른 흑피증(cyanic melasma), 약물 사용 후의 과다색소침착, 임신성 갈색반(gravidic chloasma), 및 찰상 및 화상을 포함하는 상처 또는 피부염으로 인한 염증 후 과다 색소 침착 등 일 수 있다. In addition, one aspect of the present invention provides a pharmaceutical composition for treating or preventing a pigmentation disorder comprising an extract of Pine Pine (Pine Nut) as an active ingredient. These pigmentation disorders include, but are not limited to, freckles, aging spots, liver, spots, dark spots, sunspots, daylight pigmentation, cyanic melasma, hyperpigmentation after drug use, gravidic chloasma, Hyperpigmentation after inflammation due to wounds or dermatitis involved, and the like.
본 발명의 조성물은 약학 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다. 또한 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 당해 기술 분야에 알려진 적합한 제제는 문헌(Remington's Pharmaceutical Science, 최근, Mack Publishing Company, Easton PA)에 개시되어 있는 것을 사용하는 것이 바람직하다. 포함될 수 있는 담체, 부형제 및 희석제로는 락토오스, 덱스트로오스, 수크로오스, 소르비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시 벤조에이트, 프로필히드록시 벤조에이트, 탈크, 마그네슘 스테아레이트, 광물유 등이 있다. 상기 조성물을 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 조성물에 적어도 하나 이상의 부형제, 예를 들면 전분, 칼슘 카보네이트(calcium carbonate), 수크로오스, 락토오스, 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제 등이 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. The compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions. In addition, it can be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, oral preparations such as syrups and aerosols, external preparations, suppositories and sterilized injection solutions according to a conventional method. Suitable formulations known in the art are preferably those as disclosed in Remington ' s Pharmaceutical Science, recently, Mack Publishing Company, Easton PA. Examples of carriers, excipients and diluents which may be included include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like. When the composition is formulated, it is prepared using a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, lactose, Gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, and the like. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of suppository bases include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like.
본 발명에서 사용되는 용어 "투여"는 임의의 적절한 방법으로 개체에게 소정의 본 발명의 조성물을 제공하는 것을 의미한다.The term "administering" as used herein is meant to provide any desired composition of the invention to a subject in any suitable manner.
본 발명의 약학 조성물은 연구자, 수의사, 의사 또는 기타 임상에 의해 생각되는 조직계, 동물 또는 인간에서 생물학적 또는 의학적 반응을 유도하는 유효 성분 또는 약학적 조성물의 양, 즉 치료되는 질환 또는 장애의 증상의 완화를 유도하는 양인 치료상 유효량으로 투여할 수 있다. 본 발명의 약학 조성물에 대한 치료상 유효 투여량 및 투여횟수는 원하는 효과에 따라 변화될 것임은 당업자에게 자명하다. 그러므로, 투여될 최적의 투여량은 당업자에 의해 쉽게 결정될 수 있으며, 질환의 종류, 질환의 중증도, 조성물에 함유된 유효성분 및 다른 성분의 함량, 제형의 종류, 및 환자의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여시간, 투여 경로 및 조성물의 분비율, 치료기간, 동시 사용되는 약물을 비롯한 다양한 인자에 따라 조절될 수 있다. 바람직한 효과를 위해서, 본 발명의 약학 조성물은 0.001 내지 100㎎/㎏/day의 양으로 투여할 수 있으며, 하루에 한번 투여할 수도 있고, 수 회에 나누어 투여할 수도 있다. The pharmaceutical composition of the present invention is useful as an effective ingredient or amount of a pharmaceutical composition that induces a biological or medical response in a tissue system, an animal or a human being considered by a researcher, veterinarian, physician or other clinician, RTI ID = 0.0 > effective < / RTI > amount. It will be apparent to those skilled in the art that the therapeutically effective dose and frequency of administration for the pharmaceutical compositions of the present invention will vary with the desired effect. Thus, the optimal dosage to be administered can be readily determined by those skilled in the art and will vary with the nature of the disease, the severity of the disease, the amount of active and other ingredients contained in the composition, the type of formulation, and the age, The age, body weight, sex, diet, time of administration, route of administration and fraction of the composition, duration of treatment, concurrent medication, and the like. For a desired effect, the pharmaceutical composition of the present invention may be administered in an amount of 0.001 to 100 mg / kg / day, and may be administered once a day, or divided into several doses.
본 발명의 약학 조성물은 개체에게 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관 내 주사에 의해 투여될 수 있다.
The pharmaceutical compositions of the present invention can be administered to a subject in a variety of routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection.
본 발명에 따르면, 잣외종피 추출물은 DPPH, PF, ABTS 및 TBARS를 억제하여 항산화 효과를 가지며, tyrosinase를 저해하고 B16F10세포 실험에서 tyrosine 효소단백질과 MITF 단백질의 발현을 억제함으로써 melanin 생성을 억제하여 미백효과를 나타낸다. 또한 잣외종피 추출물은 esterase 활성을 억제함으로서, elastin분자 형태를 유지시키고, ProCOL1A2를 활성화시키고, MMP-1 및 MMP-9의 발현을 억제함으로써 주름개선 효과를 나타낸다. 따라서 본 발명에 따른 잣외종피 추출물은 항산화, 미백 및 주름개선 효과에 유용한 기능성 원료로서 이용 될 수 있다.
According to the present invention, the extract of P. japonica inhibits DPPH, PF, ABTS and TBARS, inhibits tyrosinase, inhibits tyrosine enzyme protein and MITF protein expression in B16F10 cells, inhibits melanin production, . In addition, the extract of P. japonica exerts an effect of suppressing esterase activity, thereby maintaining the elastin molecular form, activating ProCOL1A2, suppressing the expression of MMP-1 and MMP-9, and improving wrinkles. Therefore, the extract of P. japonica according to the present invention can be used as a functional raw material useful for antioxidative, whitening and wrinkle-reducing effects.
도 1은 잣외종피 추출물에서의 페놀성 화합물의 함유량을 나타낸 도이다.
도 2는 DPPH법을 이용하여 잣외종피의 물 및 에탄올 추출물의 oxidative free radical 반응성을 확인한 도이다.
도 3은 잣외종피 추출물의 Phenolic 농도에 따른 DPPH 소거능의 변화를 나타낸 도이다.
도 4는 ABTS radical cation decolorization 측정을 이용한 잣외종피 추출물의 항산화 효과를 나타낸 결과이다.
도 5는 잣외종피 추출물의 Phenolic 농도에 따른 ABTS radical cation decolorization 측정한 결과이다.
도 6은 잣외종피 추출물의 antioxidant protection factor (PF)를 측정한 결과이다.
도 7은 잣외종피 추출물의 Phenolic 농도에 따른 antioxidant protection factor (PF)를 측정한 결과이다.
도 8은 잣외종피 추출물의 TBRAs 측정결과를 나타낸 도이다.
도 9는 잣외종피 추출물의 Phenolic 농도에 따른 TBRAs 측정결과를 나타낸 도이다.
도 10은 잣외종피 추출물의 수렴효과를 나타낸 도이다.
도 11은 잣외종피 추출물의 tyrosinase 저해 활성을 확인한 도이다.
도 12는 잣외종피 추출물의 처리에 따른 Melanoma cell (B16F10)의 생존율을 확인한 도이다. A: 물 추출물, B: 에탄올 추출물.
도 13은 잣외종피 추출물의 처리에 따른 Melanoma cell(B16F10)에서의 tyrosinase 저해 활성을 확인한 도이다. A: 물 추출물, B: 에탄올 추출물.
도 14는 잣외종피 추출물의 처리에 따른 Melanoma cell (B16F10)에서의 melanin 생합성 저해를 확인한 도이다. A: 물 추출물, B: 에탄올 추출물.
도 15는 잣외종피 추출물의 melanin 합성에 관여하는 tyrosinase 발현 억제 효과를 나타낸 도이다. 1, 5 및 10μg/mL의 잣외종피 추출물을 24시간 동안 처리하였다. Tyrosinase는 항체를 이용한 웨스턴 블롯을 통하여 검출하였다. 도표는 β-actin를 기준으로 정규화를 통하여 도출하였다. 각 값은 3차례의 독림된 실험값의 mean±SD으로 나타내었다.
도 16은 잣외종피 추출물의 Melanin 합성에 관여하는 microphthalmia-associated transcription factor (MITF) 발현 억제 효과를 나타낸 도이다.
도 17은 잣외종피 추출물의 Elastase 저해 활성을 확인한 도이다.
도 18은 잣외종피 추출물의 Collagenase 저해 활성을 나타낸 도이다.
도 19는 잣외종피 추출물의 처리에 따른 CCD986sk fibroblst 세포에 관한 MTT 측정 결과를 나타낸 도이다. A: 물 추출물, B: 에탄올 추출물.
도 20은 잣외종피 추출물의 처리에 따른 pro-collagen 생합성율 확인 결과이다. A: 물 추출물, B: 에탄올 추출물.
도 21은 잣외종피 추출물의 처리에 따른 procollagenase protein 발현억제 효과를 나타낸 도이다.
도 22는 잣외종피 추출물의 처리에 따른 섬유아 세포(CCD-986sk)의 주름관련 단백질(MMP-1) 및 mRNA 발현량을 확인할 결과이다. . A: 물 추출물, B: 에탄올 추출물.
도 23 및 도 24은 잣외종피 추출물 처리에 따른 fibroblast (CCD-986sk)에서의 intestitial collagenase (MMP-1)과 92kD gelatinase (MMP-9)의 protein 발현억제 효과를 나타낸 도이다.
도 25는 잣외종피 추출물 처리에 따른 TIMP-1 활성을 나타낸 결과이다. A: 물 추출물, B: 에탄올 추출물.Brief Description of the Drawings Fig. 1 is a graph showing the contents of phenolic compounds in the extrudate extract of pine nut.
FIG. 2 is a graph showing oxidative free radical reactivity of water and ethanol extracts of extruded pine nut using the DPPH method.
FIG. 3 is a graph showing changes in DPPH scavenging ability according to the Phenolic concentration of the extract of P. japonicus.
FIG. 4 shows the results of antioxidative activity of the extract of Porphyra zeaxus using ABTS radical cation decolorization.
FIG. 5 shows the results of ABTS radical cation decolorization measured according to the phenolic concentration of the extract of P. japonicus.
FIG. 6 shows the result of measuring the antioxidant protection factor (PF) of the extract of P. japonicus.
FIG. 7 shows the result of measuring the antioxidant protection factor (PF) according to the phenolic concentration of the extract of P. japonicus.
FIG. 8 is a graph showing the results of measurement of TBRAs of the extrudate extract of Pine nuts.
FIG. 9 is a graph showing the results of measurement of TBRAs according to Phenolic concentration in the extract of P. japonicus.
FIG. 10 is a graph showing convergence effects of the extract of Pine Pine Jellyfish.
Fig. 11 is a graph showing tyrosinase inhibitory activity of the extract of P. japonicum exoc.
12 is a graph showing the survival rate of the melanoma cell (B16F10) according to the treatment of the extragranular extrudate extract. A: water extract, B: ethanol extract.
FIG. 13 is a graph showing tyrosinase inhibitory activity in melanoma cell (B16F10) according to the treatment of extrudate extract of Pine nuts. A: water extract, B: ethanol extract.
FIG. 14 shows inhibition of melanin biosynthesis in melanoma cell (B16F10) according to the treatment of extruded pine nut extract. A: water extract, B: ethanol extract.
Fig. 15 is a graph showing the inhibitory effect of tyrosinase on the synthesis of melanin in the extragranular extrudate extract. 1, 5, and 10 μg / mL of pine nut extract were treated for 24 hours. Tyrosinase was detected by Western blot using antibody. Diagrams were derived from normalization based on β-actin. Each value was expressed as mean ± SD of three independent experiments.
FIG. 16 is a graph showing the inhibitory effect of MITF on the expression of melanin in the extract of P. japonica.
FIG. 17 is a view showing the elastase inhibitory activity of the extract of P. japonicus.
Fig. 18 is a graph showing collagenase inhibitory activity of the extract of P. japonicus exocarpae.
FIG. 19 is a graph showing the results of MTT measurement of CCD986sk fibroblast cells according to the treatment of extrudate extract of Pine nuts. A: water extract, B: ethanol extract.
FIG. 20 shows the results of confirming the pro-collagen biosynthesis rate according to the treatment of the extrudate extract of Pine nuts. A: water extract, B: ethanol extract.
FIG. 21 is a graph showing the inhibitory effect of procollagenase protein expression on the treatment of extrudate extract of Pine nuts.
22 shows the results of confirming the amount of wrinkle-related protein (MMP-1) and mRNA expression of fibroblast cells (CCD-986sk) treated with the extract of P. japonica exotrophs. . A: water extract, B: ethanol extract.
23 and 24 are graphs showing inhibitory effects of intestitial collagenase (MMP-1) and 92 kD gelatinase (MMP-9) on protein expression in fibroblast (CCD-986sk)
FIG. 25 shows the results of TIMP-1 activity according to the treatment with the extract of P. japonica. A: water extract, B: ethanol extract.
이하 본 발명을 실시예를 통하여 보다 상세하게 설명한다. 그러나, 이들 실시예는 본 발명을 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.
실시예Example 1. 재료의 준비 1. Preparation of materials
본 연구에 사용된 재료는 경기도 가평지역의 잣나무에 자생하여 충분히 성숙된 잣구과를 수거하여 잣구과로부터 잣구과의 외각을 둘러싸고 있는 껍질인 구과 실편을 분리하여 구과의 내부에 있는 종실(황잣)을 얻었다. 종실은 단단한 껍질인 종피를 제거하여 잣 열매(백잣)를 분리하였으며, 분리된 종피는 수세, 건조한 후 40 mesh 정도로 분쇄하여 분말로 4℃에서 보관하며 사용하였다.
The materials used in this study were naturally grown in Pinus koraiensis in Gapyeong, Gyeonggi Province, and the matured pine nuts were collected from the pine nuts and separated from the shells and shells surrounding the outer surface of the pine nuts. . The seeds of the seeds were removed by removing the seed coat, which was a hard shell. The seeds were washed with water, dried and then pulverized to about 40 mesh.
실시예 2. Example 2. 잣외종피Outer Pine Patch 추출물 제조 Extract preparation
잣외종피 열수 추출물의 경우 시료 100g에 증류수 10배 양을 가하여 85℃에서 3시간 환류냉각 추출하여 상등액과 침전물을 분리하여 3회 반복 추출하며, 에탄올 추출물의 경우 시료의 10배 양의 에탄올액을 첨가하여 실온에서 24시간 동안 침지추출한 후 상등액과 침전물을 분리하는 방법으로 3회 반복하였다. 각 추출물은 12,000rpm으로 10분간 원심분리한 후 Whatman No. 1 여과지로 여과 하였으며, 각 추출물은 농축하여 동결건조 후 냉장실에 보관하면서 본 실험의 시료로 사용하였다.
For the hot-water extract of Pine Pine Nut, 100 g of distilled water was added to 10 g of distilled water, and the mixture was heated at 85 ° C for 3 hours under reflux and cooling for extraction. The supernatant and precipitate were separated and extracted three times. In the case of ethanol extract, After immersion for 24 hours at room temperature, the supernatant was separated from the precipitate. Each extract was centrifuged at 12,000 rpm for 10 minutes. 1 filter paper, and each extract was concentrated and stored in the freezer after freeze drying, and used as a sample of this experiment.
실시예Example 3. 총 폴리페놀 함량측정 3. Total polyphenol content measurement
총 폴리페놀 화합물은 Folin-Denis 방법으로 측정하였으며, 시료 1 mL에 95% ethanol 1 mL와 증류수 5 mL를 첨가하고 1N Folin-ciocalteu reagent 0.5 mL를 넣어 잘 섞어주고, 5분간 방치한 후, Na2CO3 1 mL를 가한 후, 흡광도 725 nm에서 1시간 이내에 측정하여 gallic acid를 이용한 표준곡선으로부터 양을 환산하였다.
Polyphenol compounds were measured by the Folin-Denis method, the
실시예Example 4. 4. 잣외종피Outer Pine Patch 추출물의 Extract electronelectron donatingdonating abilityability 측정 Measure
전자공여능(EDA: electron donating ability)은 Blois의 방법을 변형하여 측정한다. 각 시료용액 2㎖에 0.2mM의 1,1-diphenyl-2-picrylhydrazyl(DPPH) 1㎖ 넣고 교반한 후 30분간 방치한 다음 517nm에서 흡광도를 측정한다. 전자공여능은 시료용액의 첨가구와 무첨가구의 흡광도 감소율로 나타낸다.The electron donating ability (EDA) is measured by modifying the Blois method. Add 1 ml of 0.2
실시예Example 5. 5. ABTSABTS radicalradical cationcation decolorizationdecolorization (( ABTSABTS ) 측정) Measure
ABTS radical cation decolorization의 측정은 Pellegrin 등의 방법에 의해 측정하였다. 즉, 7 mM ABTS와 140 mM K2S2O8을 5 mL : 88 μL로 섞어 어두운 곳에 14~16시간 방치시킨 후, 이를 absolute ethanol과 1:88비율로 섞어 734 nm에서 대조구의 흡광도 값이 0.7±0.002가 되도록 조절한 ABTS solution을 사용하였다. 시료용액과 positive control로서 BHT 각각 50 μL와 ABTS solution 1 mL를 30초 동안 섞은 후 2.5분간 incubation하여 734 nm에서 흡광도를 측정하여 아래의 식에 의해 저해율(%)을 계산하였다.ABTS radical cation decolorization was measured by Pellegrin et al. That is, 7 mM ABTS and 140 mM K 2 S 2 O 8 were mixed with 5 μL of 88 μL, left in the dark for 14-16 hours, and then mixed with absolute ethanol at a ratio of 1:88. The absorbance value of the control was 734 nm 0.7 ± 0.002 was used. As a positive control, 50 μL of BHT and 1 mL of ABTS solution were mixed for 30 seconds, incubated for 2.5 minutes, and the absorbance was measured at 734 nm. The inhibition rate (%) was calculated by the following equation.
실시예Example 6. 6. AntioxidantAntioxidant protectionprotection factorfactor (( PFPF ) 측정) Measure
PF는 Andarwulan과 Shetty의 방법으로 측정하였다. 10 mg의 β-carotene을 50 mL 의 chloroform에 녹인 용액 1 mL를 evaporator용 수기에 넣고 40℃ water bath에서 chloroform을 증류시킨 후 20 μL linoleic acid, 184 μL Tween 40과 50 mL H2O2를 가하여 emulsion을 만들고, 5 mL의 emulsion에 시료용액 100 μL를 혼합하여 vortex로 잘 섞어준 뒤 50℃에서 30분간 반응 시켜 냉각시킨 다음, 470 ㎚에서 흡광도를 측정하였다.PF Andarwulan and Shetty . 10 mL of β-carotene was dissolved in 50 mL of chloroform and 1 mL of the solution was added to the evaporator. The chloroform was distilled in a water bath at 40 ° C., and 20 μL of linoleic acid, 184 μL of
실시예 7. Example 7. ThiobarbituricThiobarbituric acidacid reactionreaction substancesubstance (( TBARsTBARs ) 측정) Measure
TBARS는 Blurge와 Aust의 방법에 따라 측정하였다. 1% linoleic acid와 1% Tween 40으로 emulsion을 만들고 emulsion 0.8 mL와 시료 0.2 mL를 섞은 후 50℃ water bath에서 10시간 반응시켰다. 반응 후 반응액 1 mL에 TBA regent [100 mL stock solution(15% trichloroacetic acid(TCA), 0.375% thiobarbituric acid, 0.25 M HCl 혼합액)에 3 mL의 2% BHT/EtOH 혼합액] 2 mL를 가하고 15분간 boiling한 다음 10분간 냉각시킨 후 15분간 1000 rpm(vision, VS-5500N)으로 원심분리하여 실온에서 10분간 방치 후 상등액을 532 ㎚에서 흡광도를 측정하였으며, TBARS값은 흡광도 수치×0.0154로 1 mL 반응혼합물에 대해서 생성된 1,1,3,3-tetraethoxy propane(TEP)의 μM으로 표시하였다. TBARS was measured according to the method of Blurge and Aust. The emulsion was prepared with 1% linoleic acid and 1
실시예Example 8. 수렴 효과 측정 8. Measurement of convergence effect
Astringent 활성 측정은 Lee 등의 방법에 따라 측정하였다. 피부 단백질과 유사한 혈액 단백질 (hemoglobin)을 사용하여, 원심분리관 용기에 각각의 시료용액과 헤모글로빈 용액을 1:1로 넣어서 진탕 혼합한 다음 1,500rpm에서 3분간 원심분리 후 576nm에서 흡광도를 측정하였다. Astringent 활성 측정은 시료용액의 첨가군와 무첨가군의 흡광도 감소율로 나타내었다.Astringent activity was measured by Lee et al. Using hemoglobin similar to skin protein, each sample solution and hemoglobin solution were mixed in a ratio of 1: 1 into a centrifuge tube, mixed with shaking, centrifuged at 1,500 rpm for 3 minutes, and absorbance was measured at 576 nm. The astringent activity measurement was expressed by the absorbance reduction rate of the sample solution addition group and the no addition group.
실시예Example 9. 미백효과 측정 9. Measurement of whitening effect
(1) (One) TyrosinaseTyrosinase 저해활성 측정 Measurement of inhibitory activity
Tyrosinase 저해활성 측정은 Yagi 등의 방법에 따라 측정하였다. 반응구는 0.175M sodium phosphate buffer (pH 6.8) 0.5mL에 10mM L-DOPA를 녹인 기질액 0.2mL 및 시료용액 0.1mL의 혼합액에 mushroom tyrosinase (110U/mL) 0.2mL을 첨가하여 25℃에서 2분간 반응시켜 반응액 중에 생성된 DOPA chrome을 475nm에서 측정하였다. Tyrosinase 저해활성은 시료용액의 첨가구와 무첨가구의 흡광도 감소율로 나타내었다.Tyrosinase inhibitory activity was measured by Yagi et al. To the reaction mixture, 0.2 mL of mushroom tyrosinase (110 U / mL) was added to a mixture of 0.2 mL of the substrate solution in which 10 mM L-DOPA was dissolved in 0.5 mL of 0.175 M sodium phosphate buffer (pH 6.8) and 0.1 mL of the sample solution and the mixture was reacted at 25 ° C. for 2 minutes And the DOPA chrome produced in the reaction solution was measured at 475 nm. The tyrosinase inhibitory activity was expressed as the absorbance reduction ratio of the sample solution and the non - added sample.
(2) (2) 잣외종피Outer Pine Patch 추출물의 Extract cellcell lineline 미백 효능 검정 Whitening efficacy test
1) 세포 생존율 측정1) Cell viability measurement
(가) 세포배양(A) Cell culture
본 실험에 이용한 각 세포의 배양은 10% fetal bovine serum (FBS)과 1% penicillin/streptomycin (100U/mL)을 첨가한 dulbeco's modified eagle‘s medium (DMEM) 배지를 사용하였으며, 37℃, 5% CO2 incubator에 적응시켜 계대 배양하였다.
Cultures of each cell used for this experiment is 10% fetal bovine serum (FBS) and 1% penicillin / streptomycin (100U / mL) a dulbeco's modified eagle's medium (DMEM ) was used as the medium, 37 ℃, 5% CO 2 was added to incubator and subcultured.
(나) (I) MTTMTT assayassay 에 의한 세포 생존율 측정Of cell survival
세포 생존율 측정은 Carmichael 등의 방법에 따라 측정하였다. 각 세포주[melanoma (B16F10), fibroblast (CCD-986sk), macrophage (Raw 264.7) cell]를 96 well plate에 0.6~8×103cells/well이 되게 0.18 mL 분주하고, 시료를 농도 별로 조제하여 0.02 mL 첨가한 후 37℃, 5% CO2 incubator에서 24시간 배양하였다. 대조군은 시료와 동량의 증류수를 첨가하여 동일한 조건으로 배양하였다. 여기에 5 mg/mL 농도로 제조한 MTT 용액 0.02 mL를 첨가하여 4시간 배양한 후 배양액을 제거하고 각 well당 DMSO:ethanol(1:1) 0.15 mL를 가하여 실온에서 30분간 반응 시킨 뒤 ELISA reader로 550nm에서 흡광도를 측정하였다.
Cell viability was measured by the method of Carmichael et al. Each cell line (melanoma (B16F10), fibroblast (CCD-986sk), and macrophage (Raw 264.7) cells) was dispensed in a 96-well plate at a concentration of 0.6 to 8 × 10 3 cells / mL, and incubated at 37 ° C in a 5% CO 2 incubator for 24 hours. In the control group, the same amount of distilled water as that of the sample was added and the cells were cultured under the same conditions. After adding 0.02 mL of MTT solution (5 mg / mL) for 4 hours, the culture solution was removed and 0.15 mL of DMSO: ethanol (1: 1) was added to each well. Absorbance at 550 nm.
2) Cellular tyrosinase 저해활성 측정2) Measurement of cellular tyrosinase inhibitory activity
Melanoma(B16F10) 세포를 각 culture dish에 가득 배양한 후, 배지를 제거하고 PBS로 세척하였다. 각 dish에 lysis buffer (67mM sodium phosphate buffer, 1% triton X-100, 0.1mM phenylmethyl sulfonyfluoride)를 100μL 첨가한 후 얼음에 방치하여 세포를 파괴시키고, 세포를 수집하여 ultra sonication 하였다. 이를 1시간 동안 방치한 후 13,200rpm에서 20분간 원심분리 하여 얻어진 상층액을 효소용액으로 사용하였다. 이를 67mM phosphate buffer(pH6.8)에 녹인 8.0mM의 L-DOPA 120uL와 시료용액 40uL를 96-well plate에 넣은 후, 67mM phosphate buffer (pH 6.8)에 녹인 효소용액 40uL을 첨가하여 37℃에서 30분간 배양한 후, 생성된 DOPA chrome의 양을 490nm에서 측정하였다.Melanoma (B16F10) cells were cultured in each culture dish, and the medium was removed and washed with PBS. 100 μl of lysis buffer (67 mM sodium phosphate buffer, 1% triton X-100, 0.1 mM phenylmethyl sulfonyfluoride) was added to each dish, and the cells were disrupted by ice, and cells were collected and subjected to ultra sonication. The supernatant obtained by centrifugation at 13,200 rpm for 20 minutes was used as an enzyme solution. 120 uL of 8.0 mM L-DOPA dissolved in 67 mM phosphate buffer (pH 6.8) and 40 uL of the sample solution were added to a 96-well plate and then 40 uL of the enzyme solution dissolved in 67 mM phosphate buffer (pH 6.8) After minute incubation, the amount of DOPA chrome produced was measured at 490 nm.
3) Melanoma cell(B16F10)에서의 melanin 생합성 저해율 측정3) Inhibition rate of melanin biosynthesis in melanoma cell (B16F10)
피부 멜라노마 세포로부터의 melanin 생합성 저해 측정은 Hosoi 등의 방법에 따라 측정하였다. DMEM 배지로 배양된 B16F10 세포를 100mm culture dish에 1×106cell/dish가 되게 분주하고 24시간 배양 후 시료를 농도별로 조제하여 2mL 첨가하고, 48시간 후에 인산완충액(pH 7.4)으로 세척하였다. 그 다음 0.25M trypsin-EDTA 용액으로 세포를 탈착한 후 수확한 세포를 1×106세포 당 1mL의 5% TCA로 처리하고, 2,500rpm으로 2회 원심분리한 후 분리된 melanin을 인산완충액으로 세척한 뒤 ether:ethanol(1:3) 1mL를 가하여 2회 원심분리 한 후 ether 1mL로 세척 건조시켰다. 건조된 melanin에 1N NaOH를 1mL 가하여 80℃에서 1시간 반응시킨 후 분광 광도계 405nm에서 흡광도를 측정하였다. Melanin 생합성저해는 시료용액의 첨가구와 무첨가구의 흡광도 감소율로 나타내었다.Measurement of inhibition of melanin biosynthesis from skin melanoma cells was performed according to the method of Hosoi et al. B16F10 cells cultured in DMEM medium were divided into 1 × 10 6 cells / dish in a 100 mm culture dish. After culturing for 24 hours, 2 mL of each sample was prepared and the cells were washed with phosphate buffer (pH 7.4) 48 hours later. After the cells were desorbed with 0.25 M trypsin-EDTA solution, the harvested cells were treated with 1 mL of 5% TCA per 1 × 10 6 cells, centrifuged twice at 2,500 rpm, and the separated melanin was washed with phosphate buffer Then, 1 mL of ether: ethanol (1: 3) was added, and the mixture was centrifuged twice. 1N NaOH was added to the dried melanin, reacted at 80 ° C for 1 hour, and the absorbance was measured at 405 nm by a spectrophotometer. The inhibition of melanin biosynthesis was expressed by the absorbance reduction ratio of the sample solution and the non - added sample.
4) Western blot을 통한 세포내 색소침착 관련 단백질의 발현 측정4) Expression of intracellular pigmentation-related proteins by Western blot
MITF, tyrosinase 단백질의 발현양의 측정은 다음과 같은 방법으로 수행 하였다. 즉, B16F10을 이용하여 culture dish에 배양한 뒤 sample 처리를 한 다음 48시간 후에 PBS로 세척한 후 원심분리 하여 세포를 수집하고, RIPA buffer를 사용하여 cell lysate를 제조하였다. 세포 lysate에 함유된 단백질의 양은 Bradford 법으로 측정하였다. 단백질 15μg을 8% polyacrylamide를 함유한 SDS-PAGE로 분리하고 PVDF membrane으로 electroblot 120 V에서 1시간을 실시하였다. 이어 PVDF membrane을 5% skim milk에서 1시간 방치한 뒤 primary antibody에서 4℃에서 overnight하여 준다. 다시 TBST로 세 번 세척한 뒤 secondary antibody를 상온에서 1시간 반응 시킨 뒤 TBST로 세번 세척하고 ECL kit (Amersham-Pharmacia)와 반응시켜 X-ray film에 노출 시킨다. X-ray film에 현상된 밴드를 LAS 4000 이미지 분석 장치를 이용하여 정량화 하였다.
The amount of MITF and tyrosinase protein expression was measured by the following method. In other words, B16F10 was cultured in a culture dish, and the sample was treated. After 48 hours, the cells were washed with PBS, centrifuged, and cell lysate was prepared using RIPA buffer. The amount of protein contained in the cell lysate was measured by the Bradford method. 15 μg of protein was separated by SDS-PAGE containing 8% polyacrylamide and electroblotted with PVDF membrane at 120 V for 1 hour. The PVDF membrane is then left in 5% skim milk for 1 hour and then overnight at 4 ° C in primary antibody. After washing three times with TBST, the secondary antibody was reacted at room temperature for 1 hour, washed three times with TBST and exposed to X-ray film by reaction with ECL kit (Amersham-Pharmacia). The developed bands on the X-ray film were quantified using a LAS 4000 image analyzer.
실시예Example 10. 주름개선 효과 10. Wrinkle improvement effect
(1) (One) ElastaseElastase 저해활성 측정 Measurement of inhibitory activity
Elastase 저해활성 측정은 Cannell 등의 방법에 따라 측정하였다. 기질로서 N-succinyl-(L-Ala)3-p-nitroanilide를 사용하여 37℃에서 20분간 기질로부터 생성되는 p-nitroanilide의 생성량을 405nm에서 측정하였다. 즉, 각 시험용액을 일정 농도가 되도록 조제하여 0.5mL씩 시험관에 취하고, 50mM tris-HCl buffer (pH 8.6)에 녹인 porcine pancreas elastase (2.5U/mL)용액 0.5mL을 가한 후 기질로 50mM tris-HCl buffer (pH 8.6)에 녹인 N-succinyl-(L-Ala)3-p-nitroanilide (0.5mg/mL)을 첨가하여 20분간 반응시켜 측정하였다. Elastase 저해활성은 시료용액의 첨가구와 무첨가구의 흡광도 감소율로 나타내었다. Elastase inhibitory activity was measured by Cannell et al. N-succinyl- (L-Ala) 3 - p- nitroanilide was used as a substrate and the amount of p- nitroanilide produced from the substrate at 37 ° C for 20 minutes was measured at 405 nm. 0.5 mL of each test solution was added to 0.5 mL of each test solution. 0.5 mL of porcine pancreas elastase (2.5 U / mL) dissolved in 50 mM tris-HCl buffer (pH 8.6) was added to the test tube. 50 mM tris- N-succinyl- (L-Ala) 3 - p- nitroanilide (0.5 mg / mL) dissolved in HCl buffer (pH 8.6) was added and the reaction was allowed to proceed for 20 minutes. Elastase inhibitory activity was expressed as the absorbance reduction ratio of the sample solution and the non - added sample.
(2) (2) CollagenaseCollagenase 저해 활성 측정 Measurement of inhibitory activity
Collagenase 저해활성 측정은 ㅉsch 등의 방법에 따라 측정하였다. 즉 반응구는 0.1M tris-HCl buffer (pH 7.5)에 4mM CaCl2를 첨가하여, 4-phenylazobenzyloxy carbonyl-Pro-Leu-Gly-Pro-D-Arg (0.3mg/mL)를 녹인 기질액 0.25mL 및 시료용액 0.1mL의 혼합액에 collagenase(0.2 mg/mL) 0.15 mL를 첨가하여 실온에서 20분간 방치한 후 6% citric acid 0.5 mL을 넣어 반응을 정지 시킨 후, ethyl acetate 1.5 mL을 첨가하여 320 nm에서 흡광도를 측정하였다. Collagenase 저해활성은 시료용액의 첨가구와 무첨가구의 흡광도 감소율로 나타내었다. Collagenase inhibitory activity was measured according to the method of Choshi et al. That is the reaction substrates dissolved phrase 0.1M tris-HCl buffer subject to 4mM CaCl 2 in (pH 7.5) was added, 4-phenylazobenzyloxy carbonyl-Pro- Leu-Gly-Pro-D-Arg (0.3mg / mL) solution, and 0.25mL 0.1 mL of collagenase (0.2 mg / mL) was added to the mixture of 0.1 mL of the sample solution. The mixture was allowed to stand at room temperature for 20 minutes, and then the reaction was stopped by adding 0.5 mL of 6% citric acid. Absorbance was measured. Collagenase inhibitory activity was expressed as the absorbance reduction ratio of the sample solution and the non - added sample.
(3) (3) 잣외종피Outer Pine Patch 추출물의 Extract cellcell lineline 주름개선 효능 검정 Wrinkle improvement efficacy test
1) 세포 생존율 측정1) Cell viability measurement
가) 세포배양A) Cell culture
본 실험에 이용한 각 세포의 배양은 10% fetal bovine serum (FBS)과 1% penicillin/streptomycin (100U/ml)을 첨가한 dulbeco's modified eagle‘s medium (DMEM) 배지를 사용하였으며, 37℃, 5% CO2 incubator에 적응시켜 계대배양하였다.
Cultures of each cell used for this experiment is 10% fetal bovine serum (FBS) and 1% penicillin / streptomycin (100U / ml) a dulbeco's modified eagle's medium (DMEM ) was used as the medium, 37 ℃, 5% CO 2 was added to incubator and subcultured.
나) MTT assay에 의한 세포 생존율 측정B) Measurement of cell viability by MTT assay
세포 생존율 측정은 Carmichael 등의 방법에 따라 측정하였다. 각 세포주[melanoma (B16F10), fibroblast (CCD-986sk), macrophage (Raw 264.7) cell]를 96 well plate에 0.6~8×103cells/well이 되게 0.18 mL 분주하고, 시료를 농도 별로 조제하여 0.02 mL 첨가한 후 37℃, 5% CO2 incubator에서 24시간 배양하였다. 대조군은 시료와 동량의 증류수를 첨가하여 동일한 조건으로 배양하였다. 여기에 5 mg/mL 농도로 제조한 MTT 용액 0.02 mL를 첨가하여 4시간 배양한 후 배양액을 제거하고 각 well당 DMSO:ethanol(1:1) 0.15 mL를 가하여 실온에서 30분간 반응 시킨 뒤 ELISA reader로 550nm에서 흡광도를 측정하였다.
Cell viability was measured by the method of Carmichael et al. Each cell line (melanoma (B16F10), fibroblast (CCD-986sk), and macrophage (Raw 264.7) cells) was dispensed in a 96-well plate at a concentration of 0.6 to 8 × 10 3 cells / mL, and incubated at 37 ° C in a 5% CO 2 incubator for 24 hours. In the control group, the same amount of distilled water as that of the sample was added and the cells were cultured under the same conditions. After adding 0.02 mL of MTT solution (5 mg / mL) for 4 hours, the culture solution was removed and 0.15 mL of DMSO: ethanol (1: 1) was added to each well. Absorbance at 550 nm.
2) 잣외종피 추출물의 피부재생효과 2) Skin regeneration effect of Extract of Pine Pine
가) ELISA kit를 이용한 주름개선 효과 측정A) Measurement of wrinkle improvement effect using ELISA kit
i) Procollagen type Ⅰ생합성 kit 측정i) Procollagen type I biosynthetic kit measurement
세포를 5x104 cells/well 농도로 12 well plate에 접종한 후, 각 well에 시료를 첨가하여 CO2 배양기에서 48시간 배양하였다. 이렇게 실험한 세포의 배양액을 모아서 실험에 사용하였다. 세포배양액내 콜라겐 생합성 정도는 procollagen type-ⅠC peptide(PIP) EIA kit를 사용하여 propeptide의 양을 측정하였다.
Cells were inoculated into 12 well plates at a concentration of 5x10 4 cells / well, and samples were added to each well and cultured in a CO 2 incubator for 48 hours. The cultures of the cells thus obtained were collected and used for the experiments. The degree of collagen biosynthesis in the cell culture medium was measured by using procollagen type-Ⅰ C peptide (PIP) EIA kit.
ii) MMP-1 & TIMP-1 활성 kit 측정ii) Measurement of MMP-1 & TIMP-1 active kit
세포를 5x104 cells/well 농도로 12 well plate에 접종한 후, 각 well에 시료를 첨가하여 CO2 배양기에서 48시간 배양하였다. 이때 MMP-1와 TIMP-1의 활성을 높이기 위하여 TNF-α를 10ng/mL의 농도로 첨가하였다. 세포의 배양액을 수거하여 MMP-1의 측정은 Amersham matrix metallproteinase-1, Human, Biotrak ELISA system(GE Healthcare)을 이용하여 측정하였다.
Cells were inoculated into 12 well plates at a concentration of 5x10 4 cells / well, and samples were added to each well and cultured in a CO 2 incubator for 48 hours. At this time, TNF-α was added at a concentration of 10 ng / mL to increase the activity of MMP-1 and TIMP-1. Cell cultures were collected and MMP-1 was measured using Amersham matrix metallproteinase-1, Human, Biotrak ELISA system (GE Healthcare).
나) Western blot을 통한 세포내 주름 관련 단백질의 발현 측정B) Expression of intracellular wrinkle-related protein by Western blot
Western blot을 이용하여 MMP-1, MMP-2, ProCOL1A2 단백질의 양을 측정하였다. CCD-986sk를 이용하여 culture dish에 배양한 뒤 sample 처리를 한 다음 48시간 후에 PBS로 세척한 후 원심분리 하여 세포를 수집하고, RIPA buffer를 사용하여 cell lysate를 제조하였다. 세포 lysate에 함유된 단백질의 양은 Bradford 법으로 측정하였다. 단백질 20μg을 10% polyacrylamide를 함유한 SDS-PAGE로 분리하고 PVDF membrane으로 electroblot 120 V에서 1시간을 실시하였다. 이어 PVDF membrane을 5% skim milk에서 1시간 방치한 뒤 primary antibody에서 4℃에서 overnight하여 준다. 다시 TBST로 세 번 세척한 뒤 secondary antibody를 상온에서 1시간 반응 시킨 뒤 TBST로 세 번 세척하고 ECL kit (Amersham-Pharmacia)와 반응시켜 X-ray film에 노출 시켰다. X-ray film에 현상된 밴드를 LAS4000 이미지 분석장치를 이용하여 정량화 하였다.
The amounts of MMP-1, MMP-2, and ProCOL1A2 proteins were measured using Western blot. After culturing in a culture dish using CCD-986sk, the cells were sampled and washed for 48 hours with PBS. Cells were collected by centrifugation and cell lysate was prepared using RIPA buffer. The amount of protein contained in the cell lysate was measured by the Bradford method. 20 μg of protein was separated by SDS-PAGE containing 10% polyacrylamide and electroblotted with PVDF membrane at 120 V for 1 hour. The PVDF membrane is then left in 5% skim milk for 1 hour and then overnight at 4 ° C in primary antibody. After washing three times with TBST, secondary antibody was reacted at room temperature for 1 hour, washed three times with TBST, and exposed to X-ray film by reaction with ECL kit (Amersham-Pharmacia). The developed bands on the X-ray film were quantified using a LAS4000 image analyzer.
실시예 11. 폐기 잣(Example 11: PinusPinus koraiensiskoraiensis SieboldSiebold etmeat ZuccZucc ) ) 종피(testa)로부터From the seed coat (testa) phenolphenol 성 물질의 추출Extraction of sex material
경기도 가평지방에서 주로 재배되는 잣나무로부터 수확된 잣구과에서 잣종실을 수확하기위해 벗겨져 활용되지 않고 버려지는 임산폐자원인 폐기 잣외종피(testa)를 추출 용매로 추출하였다. 시료의 유효성분을 보다 효율적으로 추출할 방안을 확립하기 위하여 인체에 유해하지 않은 용매로 물과 에탄올을 선택하여 추출하였으며, 에탄올 농도별로 용출되는 생리활성성분을 phenolic 화합물을 주 target으로 하여 함량을 측정하였다. 그 결과를 도 1에 나타내었다.In order to harvest the pine seedlings from the pine nuts harvested from the main pine trees cultivated in Gapyeong, Gyeonggi province, the testa, which is abandoned and abandoned, is extracted with the extraction solvent. In order to more efficiently extract the effective components of the sample, water and ethanol were selected as a non-harmful solvent. The physiologically active components eluted by ethanol concentration were measured by using phenolic compound as a main target Respectively. The results are shown in Fig.
도 1에서와 같이 50% 에탄올을 용매로 사용하였을 때 phenolic compound의 용출이 가장 높게 나타났으며, 40~50%의 농도구간에서는 용출율이 비슷한 것으로 나타났으며 추출용매의 농도가 높아질수록 phenolic compound의 용출 수율은 낮아지는 것으로 확인되었다. As shown in FIG. 1, when 50% ethanol was used as a solvent, the elution of the phenolic compound was the highest. In the concentration range of 40 to 50%, the dissolution rate was similar. As the concentration of the extraction solvent increased, It was confirmed that the elution yield was lowered.
최적조건에서의 phenolic compound의 용출량을 확인하였으며, 그 결과를 하기 표 1에 나타내었다. 표 1에서와 같이 물 추출물이 4.92±0.08 mg/mL이었고, 50% ethanol 추출물에서 5.89±0.06 mg/mL의 함량을 나타내었다.The elution amount of the phenolic compound under the optimum conditions was confirmed, and the results are shown in Table 1 below. As shown in Table 1, the content of water extract was 4.92 ± 0.08 mg / mL and that of 50% ethanol extract was 5.89 ± 0.06 mg / mL.
testa Pinus koraiensis Siebold meat Zucc .
testa
실시예Example 12. 12. 잣외종피Outer Pine Patch 추출물의 항산화 활성 Antioxidant activity of extract
(1) (One) 잣외종피Outer Pine Patch 추출물의 Extract DPPHDPPH 소거능Scatters 측정 Measure
잣외종피 물과 ethanol 추출물의 oxidative free radical 반응을 이용한 환원성 물질의 분석인 DPPH법으로 측정하였으며, 그 결과를 도 2에 나타내었다.The DPPH method, which is an analysis of reducing materials using the oxidative free radical reaction of exocrine papillae and ethanol extracts, was carried out and the results are shown in FIG.
도 2에 나타난 바와 같이 phenolic compound가 가장 많이 용출된 50% ethanol 추출물에서 최대의 DPPH 소거능을 나타내었으며, ethanol 추출물과 물 추출물 의 효과가 모두 우수하였다. As shown in FIG. 2, the highest DPPH elimination ability was obtained in the 50% ethanol extract of the phenolic compound, and the ethanol extract and water extract were excellent in the effect.
Phenolic 농도에 따른 DPPH 소거능의 변화를 살펴보았으며, 그 결과를 도 3에 나타내었다.The change of DPPH scavenging ability according to the phenolic concentration was examined, and the results are shown in FIG.
도 3에 나타난 바와 같이 첨가되는 phenolic의 함량이 높아질수록 농도의존적으로 DPPH 소거능도 증가하는 것을 알 수 있었고, 150 μg/mL 정도의 농도에서 물 추출물이 87.25%, ethanol 추출물이 97.10%의 높은 억제력을 나타내어 잣외종피 추출물은 수용성물질에 대한 항산화력이 대단히 우수한 것으로 확인되었다. 또한 에탄올 추출물은 대조구인 합성항산화제인 BHT에 비해 더 우수한 산화 억제력을 나타내어 노화방지 화장품의 소재로 활용이 가능하리라 판단되었다.
As shown in FIG. 3, DPPH elimination was found to increase in a concentration dependent manner as the amount of phenolic added was increased. In the case of the concentration of about 150 μg / mL, 87.25% of water extract and 97.10% It was confirmed that the extract of P. japonica had very good antioxidant ability against water soluble substances. In addition, ethanol extract showed better antioxidant ability than BHT, which is a control antioxidant, and could be used as a material for anti - aging cosmetics.
(2) (2) 잣외종피Outer Pine Patch 추출물의 Extract ABTSABTS radicalradical cationcation decolorizationdecolorization 측정 Measure
추출물들의 상대적인 항산화 측정은 hydrogen-donating antioxidant와 chain breacking antioxidant 모두를 측정할 수 있으며, aqueous phase와 organic phase 모두에 적용이 가능한 ABTS radical cation decolorization로 측정하였다. 이는 표준물질의 사용으로 추출물의 상대 비교가 가능하도록 potassium persulfate와의 반응에 의해 생성된 ABTS+ free radical이 추출물속의 항산화 물질에 의해 제거되어 radical 특유의 색인 청록색이 탈색되는 원리를 이용한다.Relative antioxidant activities of extracts were measured by ABTS radical cation decolorization, which can measure both hydrogen-donating antioxidants and chain breacking antioxidants, and is applicable to both aqueous and organic phases. This is based on the principle that ABTS + free radicals generated by the reaction with potassium persulfate are removed by antioxidants in the extract so that relative comparison of the extracts is possible by the use of standard substances, and the radical specific cyan color is discolored.
실험 결과를 도 4에 나타내었다.The experimental results are shown in Fig.
도 4에 나타난 바와 같이, 열수 추출물의 경우 29.93%의 억제력을 나타내었고, ethanol 추출물의 경우 50% ethanol 추출물에서 42.15%로 최대 억제력 나타내는 것으로 확인되었다. As shown in FIG. 4, 29.93% inhibitory activity was shown in the case of hot water extract and ethanol extract showed a maximum inhibitory effect in 50% ethanol extract at 42.15%.
첨가되는 phenolic compound의 함량에 따른 항산화력을 살펴보았으며, 그 결과를 도 5에 나타내었다. The antioxidant activity was examined according to the content of the phenolic compound. The results are shown in FIG.
도 5에서와 같이 첨가되는 phenolics의 농도가 높아질수록 농도 의존적으로 ABTS 저해력이 높아지는 것을 확인할 수 있었고, 50~200 μg/mL phenolics 농도의 전구간에서 대조구인 BHT에 비해 높은 항산화력을 나타내었고, 50 μg/mL phenolics의 낮은 농도에서도 물 추출물이 92.13%, 에탄올 추출물이 90.04%의 대단히 우수한 항산화력을 나타내었다. 따라서 잣외종피 추출물의 경우 저 농도에서도 수용성 물질에 대한 항산화력이 우수할 뿐만 아니라 첨가물의 농도가 높아질수록 농도 의존적인 항산화력을 나타내는 것으로 확인되었다.
As shown in FIG. 5, the higher the concentration of the phenolics added, the higher the ABTS inhibitory effect was, and the higher the antioxidative activity than the control, BHT, 50-200 μg / At low concentrations of μg / mL phenolics, water extract and ethanol extract showed 92.13% and 90.04%, respectively. Therefore, it was confirmed that the extract of P. japonicus extract showed antioxidant activity against water - soluble materials at low concentration and that the concentration of the additive increased the concentration - dependent antioxidant ability.
(3) (3) 잣외종피Outer Pine Patch 추출물의 Extract antioxidantantioxidant protectionprotection factorfactor ( ( PFPF ) 측정) Measure
β-carotene을 linoleic acid emulsion에 첨가하여 잣외종피 추출물들의 지용성 물질에 대한 항산화력을 측정한 결과를 도 6에 나타내었다.β-carotene was added to the linoleic acid emulsion to determine the antioxidant activity of lipase-exudate extracts of Pine nuts.
도 6에서와 같이 물 추출물이 1.1 PF 정도를 나타내는 것에 비해 ethanol 추출물은 농도별 전구간에서 1.1~1.2 PF 정도의 항산화력을 나타내어 BHT와 유사한 항산화력을 나타내는 것으로 측정되었다. As shown in FIG. 6, the ethanol extract showed an antioxidant power of about 1.1 to 1.2 PF in the whole range according to the concentration, while the water extract showed about 1.1 PF.
첨가되는 phenolic compound의 함량에 따른 항산화력을 살펴보았으며, 그 결과를 도 7에 나타내었다. The antioxidant activity was examined according to the content of the phenolic compound added. The results are shown in FIG.
도 7에서와 같이 첨가되는 phenolics의 농도가 높아질수록 농도 의존적으로 PF가 높아지는 것을 확인할 수 있었다. 50~200 μg/mL phenolics의 전 농도에서 물 추출물과 알콜 추출물이 각각 1.15~1.76 PF와 1.09~1.52 PF로 대조구인 BHT의 0.88~1.46 PF에 비해 상대적으로 높은 PF를 나타내어 지용성 물질에 대한 항산화력이 매우 높음을 알 수 있었다.
As shown in FIG. 7, it was confirmed that the concentration of phenolics added increases the concentration-dependent PF. The water extracts and alcohol extracts showed a higher PF of 1.15-1.76 PF and 1.09-1.52 PF, respectively, than the control BHT (0.88-1.46 PF) at 50 ~ 200 μg / mL phenolics. The antioxidant activity Was very high.
(4) (4) 잣외종피Outer Pine Patch 추출물의 Extract TBARSTBARS 측정 Measure
지용성 물질에 대한 항산화력을 측정하기 위하여 잣외종피 추출물의 TBARS를 측정하여 비교하였으며, 그 결과를 도 8에 나타내었다.In order to measure the antioxidative activity against lipid-soluble substances, TBARS of the extract of P. japonicus was measured and compared. The results are shown in FIG.
도 8에서와 같이 물 추출물과 50% ethanol 추출물에서 각각 41.59%와 66.94%의 억제력을 확인하였다.As shown in FIG. 8, inhibition of water extract and 50% ethanol extract was confirmed to be 41.59% and 66.94%, respectively.
첨가되는 phenolic compound의 함량에 따른 항산화력을 확인하였으며, 그 결과를 도 9에 나타내었다.The antioxidant activity was confirmed by the content of the phenolic compound added, and the results are shown in FIG.
도 9에서와 같이 첨가되는 phenolics의 농도가 높아질수록 농도 의존적으로 TBARS inhibition이 높아지며, 50 μg/mL phenolics의 낮은 농도에서도 90% 이상의 높은 항산화력을 나타내었다. 대조구인 BHT와 비교하여 물 추출물과 에탄올 추출물 모두 50~200 μg/mL phenolics의 농도 전 구간에서 대조구인 BHT 보다 더 우수한 항산화력을 나타내었다.
As shown in FIG. 9, the TBARS inhibition was increased in a concentration-dependent manner as the concentration of the added phenolics was increased, and the antioxidant activity was 90% or more even at a low concentration of 50 μg / mL of phenolics. Compared with the control, BHT, both water extract and ethanol extract showed better antioxidative activity than the control BHT in the concentration range of 50 ~ 200 μg / mL phenolics.
실시예Example 13. 13. 잣외종피Outer Pine Patch 추출물의 수렴효과 Convergence effect of extract
수렴작용의 원리는 피부 단백질의 고분자 flavonoids와 결합하여 가교결합을 형성하여 피부가 수축되는 현상을 말한다. 수렴이란 뜻에는 기본적으로 주름이 지고 혹은 움츠린다는 의미가 있으므로, 수렴제는 피부와 점막 혈관 등을 수축시키는 작용이 있고, 세포간극 및 림프간극을 가로막아 점액의 분비를 억제시키는 효과가 있다. 또한 수렴제는 단백질과 결합하는 성질을 가지기 때문에 일반적으로 헤모글로빈 단백질이 추출물과 결합하는 정도에 따라서 수렴성 효과 정도를 판단 할 수 있다. 이러한 수렴작용에는 외용 혹은 내용에 의해서 피부와 점막의 표면에 난용성의 피막을 형성하고 그 결과 구조를 보호하거나, 혹은 조직을 조밀하게 하여 세포막의 투과성을 감소시키는 효과가 있다. The principle of convergence is the phenomenon that the skin is contracted by binding with the polymer flavonoids of the skin protein to form crosslinks. Convergence means basically wrinkled or funny. Therefore, astringent agent has a function of contraction of skin and mucosal blood vessels, and has an effect of inhibiting secretion of mucus by blocking cell gap and lymphatic gap. In addition, since astringent agent has a property of binding to protein, it can generally judge the degree of astringent effect according to the degree of binding of hemoglobin protein to the extract. Such convergent action has the effect of forming an insoluble film on the surface of skin and mucous membranes by external use or contents and consequently protecting the structure or densifying the tissue to reduce the permeability of the cell membrane.
잣외종피 추출물의 농도를 50~200 μg/mL phenolics로 조절하여 수렴성을 측정한 결과를 도 10에 나타내었다.Fig. 10 shows the result of measuring the concentration of the extract of P. japonica by controlling the concentration of 50 ~ 200 μg / mL phenolics.
도 10에서와 같이 잣외종피 물 추출물에서는 수렴효과가 20% 미만의 효과를 나타내었으나, 에탄올 추출물에서는 200 μg/mL phenolics의 농도로 첨가하였을 때 대조구인 tannic acid의 62.4%에 비슷한 66.3%의 수렴효과를 나타내어 모공 축소를 위한 화장품 소재로 활용이 가능하리라 판단되었다.
As shown in FIG. 10, the ethanol extract had a convergence effect of 66.3%, which was similar to 62.4% of the control tannic acid when added at a concentration of 200 μg / mL phenolics. And it can be used as a cosmetic material for reducing pores.
실시예Example 14. 14. 잣외종피Outer Pine Patch 추출물의 미백 효과 측정 결과 The result of whitening effect measurement of extract
(1) (One) MushroomMushroom 유래의 Derived tyrosinasetyrosinase 저해 활성 확인 Confirm inhibitory activity
피부의 색조를 결정하는 주요한 인자인 melanin은 표피 기저층의 melanocyte라고 불리는 색소세포내의 melanosome에서 생합성 된다. 멜라닌을 합성하는데 있어서의 출발물질은 아미노산의 일종인 tyrosine이다. Tyrosine은 멜라닌 세포내에서의 tyrosinase에 의해 L-3,4-dihydroxyl phenylalanine (DOPA), DOPA quinone으로 산화된다. 그 후 DOPAquinone이 DOPA chrome, 5,6-dihydroxyindole, indole-5,6-quinone이 되고, 이어서 indole-5,6- quinone으로의 중합에 의해 melanin을 생성하는 것으로 알려져 있다. 또한 tyrosinase는 피부 멜라닌 생성에 있어서 매우 중요한 역할을 하고 있으며, melanosome 내에서 tyrosine을 산화시켜 DOPA를 만드는 tyrosine hydroxylase로, DOPA를 산화시켜 DOPA quinone을 만드는 DOPA oxidase로서 작용하여 멜라닌 중합체를 합성하는데 중요한 효소로 작용한다. Melanin, a key determinant of skin tone, is biosynthesized in melanosomes in pigmented cells called melanocytes in the epidermal basal layer. The starting material for the synthesis of melanin is tyrosine, an amino acid. Tyrosine is oxidized by tyrosinase in melanocytes to L-3,4-dihydroxyl phenylalanine (DOPA) and DOPA quinone. It is known that DOPAquinone then becomes DOPA chrome, 5,6-dihydroxyindole, and indole-5,6-quinone, and then melanin by polymerization to indole-5,6-quinone. Tyrosinase plays an important role in the formation of melanin in the skin, tyrosine hydroxylase which oxidizes tyrosine in the melanosome to form DOPA, which acts as a DOPA oxidase which oxidizes DOPA to form DOPA quinone and is an important enzyme for synthesizing melanin polymer .
사람의 피부색은 멜라닌(melanin)이나 카로틴(carotene)과 같은 색소 성분과 혈관의 분포, 각질층의 두께 등에 의해서 결정되는데, 이는 멜라닌이 피부색을 결정하는 가장 중요한 요소로 자외선을 차단하는 기능도 갖고 있지만 국소적으로 과도하게 합성되거나, 멜라닌 생성에 이상이 생기면 melasma, freckle 및 hyper-pigmentation을 유발하게 된다. 따라서 멜라닌 합성의 기질인 tyrosine을 분해하는 tyrosinase를 저해함으로서 멜라닌의 합성을 억제하여 피부의 미백효과를 볼 수 있다. 항산화 활성과 밀접한 관계가 있는 tyrosinase inhibition effect에 관해서는 최근 vitamin C, kojic acid, arbutin, hydroquinone 등의 천연 및 합성 미백제가 개발 연구되어 미백 화장품에 응용되고 있다. The skin color of a person is determined by the pigment content such as melanin or carotene, the distribution of blood vessels, the thickness of the stratum corneum, etc. This is because melanin is the most important factor for determining skin color, Excessive synthesis or anomalies in melanin production may lead to melasma, freckle and hyper-pigmentation. Therefore, by inhibiting tyrosinase, which degrades tyrosine, a substrate of melanin synthesis, it inhibits the synthesis of melanin, and thus the whitening effect of the skin can be seen. Recently, natural and synthetic whitening agents such as vitamin C, kojic acid, arbutin, and hydroquinone have been developed and applied to whitening cosmetics for the tyrosinase inhibition effect, which is closely related to antioxidant activity.
본 연구에서 잣외종피 추출물의 농도를 50, 100, 150, 200 μg/mL로 조절하여 tyrosinase inhibition test하였으며 그 결과를 도 11에 나타내었다.In this study, tyrosinase inhibition test was carried out by adjusting the concentrations of extracts of P. japonica exotrophs to 50, 100, 150, and 200 μg / mL. The results are shown in FIG.
도 11에서와 같이 잣외종피 물 추출물의 경우에는 26.4~49.9%의 비교적 높은 저해효과를, 50% ethanol 추출물에서도 물 추출물과 비슷한 21.5~47.5%의 비교적 높은 tyrosinase 저해효과를 나타내었다. 물 추출물과 에탄올 추출물 모두 첨가된 phenolic compounds의 농도가 높아질수록 미백효과가 증대하는 경향이었으며, 100 μg/mL의 저 농도에서는 현재 시중의 미백화장품에 적용하고 있는 대조구인 kojic acid 보다 약간 우수한 수준의 미백효과를 나타내었고, 150 μg/mL 이상의 고농도에서는 kojic acid와 비슷한 수준의 tyrosinase 억제효과를 나타내어, 미백효과는 대체로 우수한 것으로 판단하였다.
As shown in FIG. 11, relatively high inhibitory effect of 26.4 ~ 49.9% in the extract of P. japonicus and relatively high tyrosinase inhibitory effect of 21.5 ~ 47.5% in extract of 50% ethanol similar to that of water extract. The higher concentration of phenolic compounds added to water extracts and ethanol extracts increased the whitening effect. At low concentrations of 100 μg / mL, whitening was slightly superior to that of kojic acid, which is currently applied to commercial whitening cosmetics. The inhibitory effect of tyrosinase was similar to that of kojic acid at 150 μg / mL and above.
(2) (2) MelanomaMelanoma cellcell (B16F10)의 생존율 확인 (B16F10) survival rate
MTT 검색법은 96 well plate를 사용하여 검사 결과를 ELISA reader를 이용하여 많은 시료를 간단하게 판독할 수 있어 세포 독성 및 세포 증식 검색법으로 널리 사용되고 있으며, 세포의 대사과정에서 미토콘드리아의 탈수소 효소 작용에 의해 노란색 수용성 MTT tetrazolium을 자주색을 띠는 비수용성의 MTT formazan으로 환원시키는 방법이다. MTT detection method is widely used as a cytotoxicity and cell proliferation detection method because many samples can be easily read using an ELISA reader using a 96-well plate, and the dehydrogenase activity of mitochondria in cell metabolism To reduce the yellow water-soluble MTT tetrazolium to purple colored water-insoluble MTT formazan.
잣외종피 추출물에 의한 melanoma 세포의 생존율을 MTT assay에 의해 B16F10세포에 1, 5, 10, 25 μg/mL의 농도로 처리하였으며, 그 결과를 도 12에 나타내었다.The survival rate of melanoma cells by the extract of P. japonica was treated by MTT assay at a concentration of 1, 5, 10, 25 μg / mL in B16F10 cells. The results are shown in FIG.
도 12에서 나타난 바와 같이, 잣외종피의 물과 알콜 추출물 25 μg/mL의 농도에서 각각 46%와 37%의 세포 독성율을 나타내었으며 1, 5, 10 μg/mL에서는 90% 가까운 세포 생존율을 나타내는 것을 확인하였다.
As shown in FIG. 12, cytotoxicities of 46% and 37% were obtained at 25 μg / mL of water and alcohol extracts of pine nut exocytosis, respectively, and cell survival rates were close to 90% at 1, 5 and 10 μg / mL Respectively.
(3) (3) MelanomaMelanoma cellcell (B16F10)에서의 (B16F10) tyrosinasetyrosinase 저해 활성 확인 Confirm inhibitory activity
티로시나아제는 피부가 자외선에 노출되면 티로신에서 멜라닌 생성에 가장 중요하게 작용하는 효소로써 티로시나아제 활성을 저해함으로써 멜라닌 생성을 억제 할 수 있으며 이로 인해 기미, 주근깨, 노인성 홍반 등의 유발을 막을 수 있는 것으로 알려져 있다.Tyrosinase is an enzyme that is most important for melanin production in tyrosine when skin is exposed to ultraviolet light. By inhibiting tyrosinase activity, it can inhibit melanin production, thereby preventing the occurrence of spots, freckles, and erythema .
Tyrosinase는 Cu2 +와 결합한 효소로 동?식물, 미생물 및 사람 등에 널리 분포되어 있는 polyphenol oxidase로 멜라닌 합성 과정에서 속도를 제한하는 등 멜라닌 합성의 주요한 조절적 단계를 나타내는 효소이다. Tyrosinase is an enzyme that binds to Cu 2 + and is a polyphenol oxidase widely distributed in plants, microorganisms, and humans. It is an enzyme that represents a major regulatory step in melanin synthesis, such as limiting the rate of melanin synthesis.
잣외종피 추출물을 1, 5, 10 μg/mL의 농도로 첨가하여 생성되는 L-DOPA의 생성량을 측정한 결과를 도 13에 나타내었다. 도 13에 나타난 바와 같이, 도 12와 유사하게 잣외종피 물 추출물과 알콜 추출물의 10 μg/mL농도에서 각각 12%와 11%의 저해율을 나타내었다.
Fig. 13 shows the results of measuring the amount of L-DOPA produced by adding the extract of P. japonica extracellularis at concentrations of 1, 5 and 10 μg / mL. As shown in FIG. 13, inhibition rates of 12% and 11% at 10 μg / mL concentration of water extract of Pine nuts and alcohol extract were respectively shown in FIG. 12.
(4) (4) MelanomaMelanoma cellcell (B16F10)에서의 (B16F10) melaninmelanin 생합성 저해 확인 Confirmation of biosynthesis inhibition
사람의 피부색을 결정하는 가장 중요한 요인인 멜라닌은 피부의 광노화나 일광각화증을 억제할 뿐만 아니라, 기미, 주근깨, 검버섯 등의 부분적인 과색소침착증 (hyperpigmentation)을 일으키는 역할을 하고 있다. 멜라닌은 표피 기저층 melanocyte의 수지상 돌기를 통하여 주위의 keratinocyte로 전달되고, 피부의 각질층으로 이행한다. 피부 흑화는 피부에 존재하는 melanocyte가 UV 노출 등의 외부적 환경에 대응하여 melanin의 생성을 증가하기 때문이다. 원료 및 물질의 미백효능을 확인하기 위해 melanin 생성효소인 Tyrosinase의 효소활성 억제 탐색이 주요하게 이용되어 왔으나 최근 효소활성억제와 더불어 미백원료가 melanocyte에서 tyrosinase와 관련 효소 발현을 증가시키는 환경에서 신호전달 체계를 교란시키는 기전 연구에 대하여 많이 보고 되고 있다.Melanin, which is the most important factor in determining the skin color of a person, not only suppresses skin photoaging and sunburn keratosis but also causes partial hyperpigmentation of spots, freckles, and black spots. Melanin is transmitted to the surrounding keratinocyte through the dendrites of the melanocyte of the epidermal basal layer and migrates to the stratum corneum of the skin. Skin blackening is due to the fact that melanocytes present in the skin increase the production of melanin in response to external conditions such as UV exposure. In order to confirm the whitening effect of raw materials and substances, the inhibition of enzyme activity of tyrosinase, which is a melanin-producing enzyme, has been mainly used. However, in recent years, in addition to suppression of enzyme activity, whitening agents have been shown to increase tyrosinase and related enzyme expression in melanocyte Which is known to be involved in the development of neurodegenerative diseases.
B16F10세포내에서의 melanin 함량을 측정하기 위하여 잣외종피 물 추출물과 알콜 추출물을 1, 5, 10 μg/mL의 농도로 처리한 결과를 도 14에 나타내었다.In order to measure the content of melanin in B16F10 cells, the water extract of P. japonica and the alcohol extract were treated at the concentrations of 1, 5, and 10 μg / mL, and the results are shown in FIG.
도 14에서와 같이 추출물의 처리농도가 높아짐에 따라 control군에 비해 melanin 생합성이 저해됨을 확인하였다. 또한 1, 5 μg/mL의 낮은 농도의 처리에 의해서도 저해력이 높지는 않지만 melanin의 생합성을 저해양상이 확인되는 것으로 보아 추출물의 순도를 높인다면 미백효과를 활용한 기능성화장품 소재로 산업화할 수 있을 것이라 판단하였다.
As shown in FIG. 14, it was confirmed that the melanin biosynthesis was inhibited as compared with the control group as the treatment concentration of the extract increased. In addition, although the inhibitory effect is not high even at a low concentration of 1 and 5 μg / mL, inhibition of biosynthesis of melanin is confirmed, and if the purity of the extract is increased, it can be industrialized as a functional cosmetic material utilizing a whitening effect .
(5) (5) 잣외종피Outer Pine Patch 추출물의 Extract melaninmelanin 합성에 관여하는 Involved in synthesis tyrosinasetyrosinase 발현 억제 효과 Expression inhibitory effect
잣외종피 추출물이 pro-collagen에서 우수한 효능을 나타내어 주름관련 단백질 및 mRNA 발현량을 확인하였다. Melanin 합성에 관계된 효소인 tyrosinase에 미치는 영향을 알아보기 위하여 B16F10 mouse melanoma 세포에 농도별로 1~10μg/mL의 농도로 처리 한 후 48시간 뒤에 tyrosinase protein 발현을 western blotting으로 확인하였다. 이때 세포의 여러 조건에서도 그 발현정도의 차이가 거의 없는 house keeping gene인 β-actin을 positive control로 사용하였다. The extracts of P. japonica excelled in pro-collagen, confirming the expression of wrinkle-related proteins and mRNA. To investigate the effect of tyrosinase, an enzyme involved in the synthesis of melanin, tyrosinase protein expression was determined by western blotting after 48 h of treatment with B10F10 mouse melanoma cells at a concentration of 1 to 10 μg / mL. Β-actin, a house keeping gene, was used as a positive control with little difference in the expression level of the cells under various conditions.
그 결과를 도 15에 나타내었다.The results are shown in Fig.
도 15에 나타난 바와 같이, 추출물을 처리 하지 않은 B16F10군에서는 각 전사인자의 단백질 발현이 증가하였지만, 잣외종피 추출물을 처리한 B16F10군에서는 tyrosinase protein의 발현이 처리하지 않은 군보다 농도 의존적으로 감소하여 10 μg/mL의 농도에서는 물과 알콜 추출물에서 30% 이상의 발현 억제 효과를 나타내었다. 따라서 잣외종피 추출물이 mushroom tyrosinase의 발현을 농도 의존적으로 감소시키는 결과를 나타냄에 따라 잣외종피 추출물은 tyrosinase의 발현을 단계적으로 저해시킴으로서 멜라닌 생성 억제에 효과가 있음을 확인 할 수 있었다.
As shown in FIG. 15, the protein expression of each transcription factor was increased in the B16F10 group not treated with the extract, but the expression of tyrosinase protein was decreased in the B16F10 group treated with the extracellular extract of pine nuts, At the concentration of μg / mL, the water and alcohol extract showed 30% or more inhibitory effect. Therefore, it was concluded that the extract of P. japonica extract decreased the expression of mushroom tyrosinase in a dose - dependent manner. Thus, it was confirmed that the extract of P. japonicum excellently inhibited the production of tyrosinase by inhibiting the expression of tyrosinase.
(6) (6) MelaninMelanin 합성에 관여하는 Involved in synthesis microphthalmiamicrophthalmia -- associatedassociated transcriptiontranscription factorfactor (MITF) 발현 억제 효과 (MITF) expression inhibitory effect
Melanin 생합성 신호전달 체계에는 매우 다양한 신호전달물질이 관여하고 있다. Melanin은 몇 가지 세포내 신호전달 기전을 통하여 합성되며, 그 중에서 cAMP (cyclic adenosine monophosphate)/PKA (protein kinase A)경로가 melanin 합성의 주요 경로로서 UV에 피부가 노출되었을 때 melanin세포의 cAMP가 증가되고 하류 신호전달 물질인 PKA를 활성화 시키며, CREB (cAMP response element binding protein)을 거쳐 MITF (microphthalmia -associatedtranscription factor)의 발현을 증가시킨다. MITF는 melanin 합성 과정에서 중요한 전사 조절 인자로 tyrosinase의 전사를 촉진한다. A wide variety of signaling molecules are involved in the melanin biosynthetic signaling system. Melanin is synthesized through several intracellular signal transduction mechanisms. Among them, cAMP (cyclic adenosine monophosphate) / PKA (protein kinase A) pathway is the main pathway for melanin synthesis. And activates PKA, a downstream signaling substance, and increases the expression of MITF (microphthalmia -associated transcription factor) via CREB (cAMP response element binding protein). MITF promotes the transcription of tyrosinase as an important transcription factor in melanin synthesis.
잣외종피 추출물의 미백효과검증을 위해 melanin 합성과 관련된 MITF의 발현에 미치는 영향을 알아보기 위하여 B16F10 mouse melanoma 세포에 농도별로 1~10μg/mL의 농도로 처리 한 후 48시간 뒤에 MITF protein 발현을 western blotting으로 확인하였다. 이때 세포의 여러 조건에서도 그 발현정도의 차이가 거의 없는 house keeping gene인 β-actin을 positive control로 사용하였다. 그 결과를 도 16에 나타내었다.To examine the effect of MITF on the expression of melanin for the whitening effect of the extract of P. japonicus, the B16F10 mouse melanoma cells were treated with a concentration of 1 ~ 10 μg / mL for each concentration, and the expression of MITF protein was western blotted Respectively. Β-actin, a house keeping gene, was used as a positive control with little difference in the expression level of the cells under various conditions. The results are shown in Fig.
도 16에서와 같이 추출물을 처리 하지 않은 B16F10군에서는 각 전사인자의 단백질 발현이 증가하였지만, 잣외종피 추출물을 처리한 B16F10군에서는 MITF protein의 발현이 처리하지 않은 군보다 농도 의존적으로 감소하여 10 μg/mL의 농도에서는 물 추출물은 약 40% 억제, 알콜 추출물은 약 30% 억제효과를 나타내어, 물 추출물과 알콜 추출물 모두 전사조절 인자인 MITF 발현의 억제에 효과적임을 확인하였다. 따라서 잣외종피 추출물이 MITF의 발현을 농도 의존적으로 감소시키는 결과를 나타냄에 따라 잣외종피 추출물은 멜라닌 생성 억제에 효과가 있음을 확인 할 수 있었다. 이는 잣외종피 추출물이 미백효과 검증기전 연구에서 MITF 발현 억제를 통하여 tyrosinase의 단백질 발현이 감소되는 것으로 확인되었다.
As shown in Fig. 16, the protein expression of each transcription factor was increased in the B16F10 group without the extract treatment, but the expression of MITF protein was decreased in the B16F10 group treated with the extract of Porphyrae japonica extract in a concentration-dependent manner, mL, water extracts showed about 40% inhibition and alcohol extracts showed about 30% inhibition. Water extracts and alcohol extracts were effective in inhibiting the expression of MITF, a transcription factor. Thus, the extract of P. japonica extract showed a concentration - dependent decrease in MITF expression, indicating that the extract of P. japonica was effective in inhibiting melanogenesis. It was confirmed that the protein expression of tyrosinase was decreased by suppression of MITF expression in a study on the whitening effect of pine nut extract.
실시예Example 15. 15. 잣외종피Outer Pine Patch 추출물의 주름개선 효과 측정 결과 Wrinkle improvement effect measurement result of extract
(1) (One) ElastaseElastase 저해 활성 확인 Confirm inhibitory activity
피부는 주름 증가와 탄력감소, 색소 침착 등이 노화의 대표적인 형태로, 그 중 가장 대표적인 노화의 현상은 바로 주름이다. 인체의 중성구 과립구내에 존재하는 elastase는 진피 내 피부탄력을 유지하는데 주요한 기질 단백질인 엘라스틴을 분해하는 효소이며, elastase가 작용함에 따라 피부조직내의 elastin을 분해함으로서 피부의 탄력성이나 싱싱함을 잃게 하고, 주름과 거칠어짐을 발생하여 피부의 노화를 촉진한다. 따라서 elastase의 활성을 억제함으로서 피부노화를 지연시킬 수 있을 것이다. Skin is a representative form of aging, such as wrinkles increase, elasticity decrease, pigmentation, etc. The most typical phenomenon of aging is wrinkles. The elastase present in the neutrophil granules of the human body is an enzyme that decomposes elastin, which is the main substrate protein for maintaining skin elasticity in the dermis. As the elastase acts, it decomposes elastin in the skin tissue, thereby losing elasticity and freshness of the skin. It causes roughness and promotes aging of the skin. Thus, inhibition of elastase activity may delay skin aging.
Elastase는 다른 중요한 기질 단백질인 콜라겐을 분해할 수 있는 비특이적 가수분해 효소이며, elastase 저해제는 피부 주름을 개선하는 작용을 나타내며, 현재 ursolic acid 등이 elastase 저해제로 이용되고 있다. 또한 Cannell 등은 체내의 엘라스틴을 분해하는 백혈구 과립 효소 중의 하나로 이상조직에서는 그 효소의 활성이 극히 높아 조직 파괴에 직접적인 원인이 되어 피부주름 및 탄력성 소실을 유발한다고 하였다. 따라서 elastase 저해활성을 측정함으로서 주름개선의 효과를 기대할 수 있다. Elastase는 기질인 N-succinyl- (Ala)-3-p-nitroanilide를 이용하여 nitroanilide (NA)가 분해되면서 생기는 색의 변화를 흡광도를 이용하여 측정해서 엘라스타제 활성을 확인한다. 가장 널리 활용되고 있는 방법이나 생체 엘라스틴 대신 합성된 기질을 이용하여 활성을 측정한다는 단점이 있다. Elastase is a nonspecific hydrolytic enzyme capable of degrading collagen, another important substrate protein. Elastase inhibitors improve skin wrinkles. Ursolic acid is currently used as an elastase inhibitor. In addition, Cannell et al. Is one of the leucocyte granulase enzymes that degrade elastin in the body. In the abnormal tissues, the activity of the enzymes is extremely high, which is a direct cause of tissue destruction, resulting in wrinkles and loss of elasticity. Therefore, the effect of improving wrinkles can be expected by measuring the elastase inhibitory activity. Elastase activity is measured by measuring the change in color caused by the decomposition of nitroanilide (NA) using the substrate N-succinyl- (Ala) -3-p-nitroanilide using absorbance. It has the disadvantage of measuring the activity using the most widely used method or synthesized substrate instead of bioelastic.
Elastase 저해제로는 ursolic acid 등이 elastase 저해제로 이용되고 있는데, ursolic acid는 물이나 오일 등의 용매에는 잘 녹지 않는 물성을 가지고 있기 때문에 제제화하기 어려워 일반적으로 사용하기 어려운 문제점이 있다. Elastase inhibitors include ursolic acid is used as an elastase inhibitor. ursolic acid is difficult to formulate because it has insoluble properties in a solvent such as water or oil, so that it is generally difficult to use.
잣외종피 추출물의 농도를 50~200 μg/mL phenolics의 농도로 조절하여 elastase 저해활성 측정하였으며, 그 결과를 도 17에 나타내었다.The elastase inhibitory activity was measured by adjusting the concentration of the extrudate extract of Pine nuts to 50-200 μg / mL phenolics. The results are shown in FIG.
도 17에서와 같이 잣외종피 추출물의 50 μg/mL phenolis의 첨가농도에서 200 μg/mL로 높아짐에 따라 농도 의존적으로 elastase에 대한 저해 활성이 높아짐을 확인하였으며, 50% ethanol 200 μg/mL phenolics의 첨가농도에서 28.47%의 저해력을 확인할 수 있었다.
As shown in FIG. 17, it was confirmed that the inhibitory activity against elastase was increased in a concentration-dependent manner as the concentration of 50 μg / mL phenolis was increased from 200 μg / mL to 50 μg / mL of phenolics The inhibitory power of 28.47% was confirmed.
(2) (2) CollagenaseCollagenase 저해 활성 Inhibitory activity
세포 외 기질(extracellular matrix)의 주요 구성 성분인 collagen은 피부의 섬유아세포에서 생성되는 주요 기질 단백질이다. 또한 생체 단백질 총 중량의 약 30%를 차지하는 중요한 단백질로서 견고한 3중 나선구조를 가지고 있다. Collagen은 피부, 건(tendon), 뼈 및 치아의 유기 물질의 대부분을 형성하는데, 특히 뼈와 피부의 진피에 그 포함량이 높다. Collagen의 주된 기능으로는 피부의 기계적 견고성, 결합조직의 저항력과 조직의 결합력, 세포 접착의 지탱, 세포 분할과 분화의 유도 등이 알려져 있다. 이러한 collagen은 연령 및 자외선 조사에 의한 광노화에 의해 감소하며, 이는 피부의 주름 형성과 밀접한 연관이 있다고 알려져 있다. 또한 collagen은 트립신 등의 단백질 분해효소의 작용을 받지 않으나, collagenase에 의해 분해된다는 보고가 있다.Collagen, a major component of the extracellular matrix, is a major substrate protein produced by the fibroblasts of the skin. It is also an important protein that accounts for about 30% of the total biomass protein weight, and has a solid triple helix structure. Collagen forms most of the organic matter in the skin, tendons, bones and teeth, especially in the bones and dermis of the skin. The main functions of collagen are known to be mechanical rigidity of skin, resistance of connective tissues and binding force of tissues, support of cell adhesion, induction of cell division and differentiation. Such collagen is reduced by aging and photoaging by ultraviolet irradiation, which is known to be closely related to wrinkling of the skin. In addition, collagen is not affected by proteases such as trypsin but is reported to be degraded by collagenase.
잣외종피 추출물의 농도를 50~200 μg/mL phenolics로 조절하여 collagenase 저해활성을 측정하였으며, 그 결과를 도 18에 나타내었다.The concentration of the extract of P. japonica was adjusted to 50 ~ 200 μg / mL phenolics to measure collagenase inhibitory activity. The results are shown in FIG.
도 18에서와 같이 잣외종피 물 추출물에서는 3.04~7.39%의 collagenase 억제효과가 확인 되었고, 에탄올 추출물에서는 3.53~51.69%의 저해효과가 확인되어 알콜 추출물이 물 추출물에 비해 collagenase에 대한 억제 효과는 더 우수하였다. 이러한 결과는 폐기 잣외종피 추출물이 피부 내에서 collagenase의 활성을 억제함으로서 collagen의 분해를 막아 주름개선을 위한 기능성 화장품 소재로 활용이 가능할 것으로 판단하였다.
As shown in Fig. 18, the collagenase inhibitory effect was 3.04 ~ 7.39% in the extract of P. japonicus extract and 3.53 ~ 51.69% in the ethanol extract, and the inhibitory effect of the alcohol extract on collagenase Respectively. These results suggest that the extracts of P. japonica inhibit collagenase activity in the skin and inhibit degradation of collagen, so that it can be used as a functional cosmetic material to improve wrinkles.
(3) (3) FibroblastFibroblast cellcell ( ( CCDCCD -986-986 sksk )의 생존율 확인) Survival rate confirmation
1) CCD986sk fibroblst 세포에 관한 MTT 측정 결과1) MTT measurement results on CCD986sk fibroblst cells
MTT 검색법은 96 well plate를 사용하여 검사 결과를 ELISA reader를 이용하여 많은 시료를 간단하게 판독할 수 있어 세포 독성 및 세포 증식 검색법으로 널리 사용되고 있으며, 세포의 대사과정에서 미토콘드리아의 탈수소 효소 작용에 의해 노란색 수용성 MTT tetrazolium을 자주색을 띠는 비수용성의 MTT formazan으로 환원시키는 방법이다. MTT detection method is widely used as a cytotoxicity and cell proliferation detection method because many samples can be easily read using an ELISA reader using a 96-well plate, and the dehydrogenase activity of mitochondria in cell metabolism To reduce the yellow water-soluble MTT tetrazolium to purple colored water-insoluble MTT formazan.
잣외종피 추출물의 세포 생존율을 측정하기 위하여 CCD-986sk세포에 1, 5, 10, 25 μg/mL의 농도로 처리한 결과를 도 19에 나타내었다.In order to measure the cell survival rate of the extract of P. japonicus, the concentration of 1, 5, 10, 25 μg / mL was applied to CCD-986sk cells, and the result is shown in FIG.
도 19에 나타난 바와 같이, 물 추출물과 알콜 추출물 모두 25 μg/mL의 농도에서 25% 정도의 세포 독성을 나타내었으나 1, 5, 10 μg/mL의 농도에서는 높은 생존율을 나타내는 것을 확인하였다.
As shown in FIG. 19, both the water extract and the alcohol extract showed cytotoxicity of about 25% at a concentration of 25 μg / mL, but the survival rate was high at the concentrations of 1, 5, and 10 μg / mL.
(4) (4) ELISAELISA kitkit 를 이용한 Using fibroblastfibroblast ( ( CCDCCD -986-986 sksk )에서의 ) In procollagenprocollagen typetype Ⅰ생합성 I Biosynthesis kitkit 측정 결과Measurement result
콜라겐은 대부분 피부의 진피층에 존재하며, 피부 전체 건조중량의 약 70~80%를 차지하고 있어, 세포외 기질의 대부분을 차지하면서 피부를 지지하는 역할을 한다. 그러나 자연 노화에 따른 세포 활성의 감소와 같은 내적 요인에 의해 콜라겐의 생합성이 감소되고, 여러 가지 유해 환경에 의한 스트레스의 증가 및 태양 광선에 의한 활성 산소종의 증가와 같은 외적 요인에 의해 분해가 가속화 되어 피부 기질이 파괴되면서 주름이 생성된다. 또한 콜라겐은 상처 치유에 있어서 중요한 역할을 담당하며, 손상된 상피에서 콜라겐의 합성을 촉진시키면서 상처를 신속하게 흉터없이 회복할 수 있다. 현재까지 밝혀진 콜라겐 합성 촉진 물질 중 가장 대표적인 것으로는 centella asiatica의 주성분들인 asiaticoside, asiatic acid, madecasic acid 등을 들 수 있다. Most of the collagen is present in the dermis of the skin and accounts for about 70 to 80% of the dry weight of the skin. It plays a role of supporting the skin occupying most of the extracellular matrix. However, degradation of collagen is accelerated by extrinsic factors such as decrease of collagen biosynthesis due to internal factors such as decrease of cell activity due to natural aging, increase of stress due to various harmful environments, and increase of active oxygen species by sunlight And the skin substrate is destroyed to form wrinkles. Collagen also plays an important role in healing wounds and can quickly restore scars without scarring, promoting the synthesis of collagen in damaged epithelium. The most prominent examples of collagen synthesis promoting substances that have been found so far include asiaticoside, asiatic acid, and madecasic acid, which are the major components of centella asiatica.
CCD-986sk세포내에서의 잣외종피 물과 알콜 추출물 1, 5, 10 μg/mL 농도에서의 pro-collagen의 합성을 측정한 결과를 도 20에 나타내었다.The results of measurement of the pro-collagen synthesis at concentrations of 1, 5, and 10 μg / mL of extraneous pine nut and alcohol extracts in CCD-986sk cells are shown in FIG.
도 20에서와 같이 1~10 μg/mL의 농도에서 농도 의존적으로 추출물이 pro-collagen 생합성을 나타내었으며, 특히 10 μg/mL의 농도에서 각각 50%와 62%의 생합성율을 나타내어 동일농도에서 대조물질인 epigallocatechin-3-O- gallate (EGCG) 보다는 낮으나 비교적 우수한 pro-collagen 생합성을 나타내는 것을 확인할 수 있었다.
As shown in FIG. 20, the extracts showed pro-collagen biosynthesis in a concentration dependent manner at a concentration of 1 to 10 μg / mL. In particular, the biosynthesis rate was 50% and 62% at a concentration of 10 μg / (EGCG), but the pro-collagen biosynthesis was relatively superior to epigallocatechin-3-O-gallate (EGCG).
(5) (5) WesternWestern blottingblotting analysis분석 를 이용한 Using fibroblastfibroblast ( ( CCDCCD -986-986 sksk )에서의 procollagenase ) In procollagenase proteinprotein 발현억제 효과 Expression inhibitory effect
피부의 주름은 콜라겐의 생합성이 감소되고, 유해 환경과 같은 여러 가지 외적 요인에 의해 collagen의 분해가 가속화 되어 피부 기질이 파괴되면서 생성된다. 또한 콜라겐의 생합성은 상처 치유에 있어서 중요한 역할을 담당하며, 손상된 상피에서 콜라겐의 합성을 촉진시켜 상처를 신속하게 회복시켜준다.The wrinkles of the skin are formed by collagen biosynthesis being reduced, collagen degradation accelerated by various extrinsic factors such as harmful environment, and destruction of the skin substrate. The biosynthesis of collagen plays an important role in wound healing and promotes the synthesis of collagen in the damaged epithelium, thus promptly restoring the wound.
따라서 잣외종피 추출물이 콜라겐의 생합성에 관계된 효소인 procollagenase의 효소 단백질 발현에 미치는 영향을 알아보기 위하여 CCD-986sk 세포내에서의 procollagenase protein 발현을 western blotting으로 확인 하였다. 이때 세포의 여러 조건에서도 그 발현정도의 차이가 거의 없는 house keeping gene인 GAPDH를 positive control로 사용하였다. 그 결과를 도 21에 나타내었다.Therefore, we investigated the effect of the extract of P. japonica on the expression of the enzyme protein of procollagenase, an enzyme involved in biosynthesis of collagen, by Western blotting the expression of procollagenase protein in CCD-986sk cells. GAPDH, a house keeping gene, was used as a positive control with little difference in the expression level even in various cell conditions. The results are shown in Fig.
도 21에 나타난 바와 같이, UV-B를 조사한 control군에서는 procollagenase의 발현정도가 normal군에 비해 현저하게 감소하는 것이 확인되었다. 잣외종피 추출물을 처리한 CCD-986sk 세포군에서는 각 전사인자의 단백질 발현양이 첨가되는 추출물의 농도 의존적으로 증가하였으며, 물 추출물에서는 효과가 거의 없었으나 알코올 추출물의 10 μg/mL 처리 농도에서는 거의 normal군에 가깝게 발현정도로 회복되는 것으로 확인되었다. 따라서 잣외종피 알코올 추출물은 손상된 procollagenase를 활성화시킴으로 인해 콜라겐의 합성을 촉진시켜 생성된 주름의 개선 효과를 나타내며, 손상된 상피에서의 회복을 촉진시켜주는 작용을 수행하는 효과가 우수함을 확인 할 수 있었다.
As shown in Fig. 21, in the control group irradiated with UV-B, it was confirmed that the degree of procollagenase expression was remarkably decreased compared to the normal group. In the CCD-986sk cell line treated with pine nut extract, the protein expression of each transcription factor was increased in a concentration-dependent manner and the water extract had little effect. However, at 10 μg / And the expression level of the protein was restored to the expression level. Therefore, it was confirmed that the alcohol extract of P. japonica exerts an effect of promoting the synthesis of collagen by activating the damaged procollagenase, improving the wrinkles generated, and promoting the recovery from damaged epithelium.
(6) (6) 섬유아Fiber 세포( cell( CCDCCD -986-986 sksk )의 주름관련 단백질() Wrinkle-related protein ( MMPMMP -1) 및 -1) and mRNAmRNA 발현량 확인 Check the expression level
피부 세포의 결합 조직을 구성하는 성분 중 collagen은 피부 건조 중량의 90%정도를 차지하는 주요 구성 단백질이다. 따라서 collagen의 분해는 결합 조직의 탄력 저하와 주름 생성 등에 직접적인 영향을 미친다. 또한 노화와 관련된 인자인 MAPK에 가장 많은 영향을 받은 인자는 c-fos이며 이는 p38의 영향을 받는다. 이러한 요인들이 활성화되면 MMPs의 발현을 강력히 조절한다. 체내에서 생성되는 수종의 MMPs가운데 MMP-1은 collagen에 특이적으로 작용하는 protease로서 MMP-1 활성을 억제하면 collagen의 분해를 감소시키며 피부 조직의 탄력을 유지하고 주름 생성을 예방할 수 있는 것으로 알려져 있다. Collagen is a major constituent protein that accounts for 90% of skin dry weight. Therefore, degradation of collagen directly affects the elasticity of the connective tissue and wrinkle formation. In addition, the factor most affected by MAPK, which is an aging-related factor, is c-fos, which is affected by p38. Activation of these factors strongly regulates the expression of MMPs. Among the several MMPs produced in the body, MMP-1 is a protease specifically acting on collagen. It is known that inhibition of MMP-1 activity reduces collagen degradation, maintains elasticity of skin tissue and prevents wrinkle formation .
CCD-986sk 세포 내에서의 MMP-1의 활성을 측정한 결과를 도 22에 나타내었다.The results of measuring the activity of MMP-1 in CCD-986sk cells are shown in Fig.
도 22에에서와 같이 잣외종피 물과 알콜 추출물 모두 농도 의존적으로 저해율을 나타내는 것을 확인할 수 있었다. 또한 물 추출물에 비해 알콜 추출물이 상대적으로 MMP-1의 발현 억제 효과가 더 우수한 효능을 나타냄을 확인하였다.
As shown in FIG. 22, it was confirmed that both the extrudate and the alcohol extract showed inhibition rates in a concentration-dependent manner. In addition, it was confirmed that the alcohol extracts showed more excellent inhibitory effect on the expression of MMP-1 than water extracts.
(7) (7) WesternWestern blottingblotting analysis분석 를 이용한 Using fibroblastfibroblast ( ( CCDCCD -986-986 sksk )에서의 ) In intestitialintestinal collagenase ( collagenase ( MMPMMP -1)과 92-1) and 92 kDkD gelatinasegelatinase ( ( MMPMMP -9)의 -9) of proteinprotein 발현억제 효과 Expression inhibitory effect
피부 진피 내 세포 외 기질 단백질(extracellular matrix)의 재구성에는 여러 생체 반응이 관하며, 이들 기질단백질 들이 피부의 구조와 탄력성을 유지하는데 중요한 역할을 한다. 이중 특히 MMPs가 기질 단백질들을 분해하는 중요한 역할을 하고 있으며 intestitial collagenase (MMP-1), 72kD gelatinase (MMP-2), 92kD gelatinase (MMP-9), neutrophil collagenase (MMP-8), collagenase (MMP-13) 등 26가지 이상의 MMPs가 이미 알려져 있다. 과다한 자외선에 노출된 피부에서는 MMPs의 발현이 증가되며, 증가된 MMPs가 피부를 구성하고 있는 교원질을 분해하여 기질 단백질의 결핍을 초래하게 됨으로써 피부노화와 더불어 주름이 발생하게 된다.Reconstruction of extracellular matrix proteins in the dermis involves a variety of biological reactions, and these substrate proteins play an important role in maintaining the structure and resilience of the skin. (MMP-1), 72 kD gelatinase (MMP-2), 92 kD gelatinase (MMP-9), neutrophil collagenase (MMP-8) and collagenase (MMP-9) 13) and more than 26 MMPs are already known. In skin exposed to excessive ultraviolet rays, the expression of MMPs is increased, and the increased MMPs break down the collagen that constitutes the skin, resulting in the deficiency of the substrate protein, thereby causing wrinkles along with aging of the skin.
피부 결합 조직 중 90%를 차지하는 collagen에 특이적으로 작용하는 protease로서 MMP-1 활성을 억제하면 collagen의 분해를 감소시키며 피부 조직의 탄력을 유지하고 주름 생성을 예방할 수 있다. 또한 MMPs 효소 중 72kD gelatinase (MMP-2)와 같은 계열로 92kD gelatinase인 MMP-9도 진피층의 세포간 material로 존재하는 gelatin의 분해를 초래하는 gelatinase의 활성을 유도하는 효소로 역시 주름의 발생에 관여하는 중요한 인자이다. 그러므로 MMP-1과 더불어 MMP-9의 활성을 억제하면 collagen의 분해를 감소시키며 피부 조직의 탄력을 유지하고 주름 생성을 예방할 수 있는 것으로 알려져 있다. 따라서 잣외종피 추출물이 MMP-1과 MMP-9 단백질 발현에 미치는 영향을 알아보기 위하여 CCD-986sk 세포내에서의 MMP-1과 MMP-9 protein 발현을 western blotting으로 확인 하였다. 이때 세포의 여러 조건에서도 그 발현정도의 차이가 거의 없는 house keeping gene인 β-actin을 positive control로 사용하였다. 그 결과를 도 23에 나타내었다.Inhibition of MMP-1 activity as a protease specifically acting on collagen, which accounts for 90% of skin connective tissues, can reduce collagen degradation, maintain skin elasticity and prevent wrinkle formation. In addition, MMP-9, a 92 kD gelatinase in the same order as 72 kD gelatinase (MMP-2) among enzymes, induces the activity of gelatinase, which causes decomposition of gelatin existing as an intercellular material of the dermal layer. Is an important factor. Therefore, inhibiting the activity of MMP-9 in combination with MMP-1 has been shown to reduce collagen degradation, maintain skin elasticity and prevent wrinkle formation. Therefore, the expression of MMP-1 and MMP-9 protein in CCD-986sk cells was confirmed by western blotting in order to investigate the effect of the extract of P. japonica on MMP-1 and MMP-9 protein expression. Β-actin, a house keeping gene, was used as a positive control with little difference in the expression level of the cells under various conditions. The results are shown in Fig.
도 23에서 보는 바와 같이 UV-B를 조사한 control군에서는 MMP-1의 발현정도가 normal군에 비해 현저하게 증가되어 있는 것이 확인되었다. 잣외종피 추출물을 처리한 CCD-986sk 세포군에서는 각 전사인자의 단백질 발현양이 첨가되는 추출물의 농도 의존적으로 감소하였으며, 물 추출물에 비해 알콜 추출물의 효능이 더 우수하였으며, 알코올 추출물 10 μg/mL의 농도에서는 현재 시중에서 기능성 화장품에 이용되고 있는 EGCG보다 억제율이 더 우수한 것을 확인 할 수 있었다. 따라서 폐기 잣외종피 추출물은 MMP-1 단백질의 발현을 억제하여 결과적으로 collagenase의 억제를 유도함으로서 주름의 개선 효과를 나타내며, 손상된 상피에서의 회복을 촉진시켜주는 작용을 수행하는 효과가 있음을 확인 할 수 있었다. As shown in FIG. 23, it was confirmed that the expression level of MMP-1 was markedly increased in the control group irradiated with UV-B compared with the normal group. In the CCD-986sk cell line treated with the extract of Porphyra japonica, the protein expression level of each transcription factor was decreased depending on the concentration of the extract added. The alcohol extract was more effective than the water extract and the concentration of alcohol extract was 10 μg / mL , It was confirmed that the inhibition rate is better than that of EGCG which is currently used in functional cosmetics in the market. Therefore, it is possible to confirm that the extract of exocytotic papillae inhibits the expression of MMP-1 protein and consequently inhibits collagenase, thereby exhibiting an effect of improving wrinkles and promoting the recovery of damaged epithelium there was.
MMP-9의 경우 역시 control군에서 protein의 발현정도가 normal 군에 비해 현저하게 증가되어 있는 것이 확인되었다. In the case of MMP-9, it was also confirmed that the expression level of protein in the control group was significantly increased as compared with that of the normal group.
또한, 잣외종피 추출물을 처리한 CCD-986sk 세포군에서는 도 24에 나타난 바와 같이, 각 전사인자의 단백질 발현양이 첨가되는 추출물의 농도 의존적으로 감소하였으며, 10 μg/mL의 농도에서는 물 추출물에서 현재 시중에서 기능성 화장품에 이용되고 있는 EGCG와 유사한 억제율을 나타내었고, 알콜 추출물의 경우 대조구인 EGCG 보다 더 우수한 억제력을 나타내는 것을 확인 할 수 있었다. 따라서 잣외종피 추출물은 MMP-9 단백질의 발현을 억제하여 결과적으로 주름의 개선 효과를 나타냄을 확인 할 수 있었다.
In the CCD-986sk cell group treated with the extract of P. japonica, the expression level of the protein expressed by each transcription factor was decreased in a concentration-dependent manner. As shown in Fig. 24, the expression level of 10 μg / The inhibitory effect was similar to that of EGCG used in functional cosmetics. The alcohol extract showed better inhibitory effect than EGCG, which is a control. Therefore, it was confirmed that the extract of P. japonica exerts an effect of suppressing the expression of MMP-9 protein and consequently improving wrinkles.
(8) (8) TIMPTIMP -1 활성 -1 activity kitkit 측정 결과 Measurement result
MMP 활성화는 α2-macroglobulin과 RECK등과 같은 비 특이적 저해제뿐만 아니라 tissue inhibitors of metallo-proteinase에 의해 특이적으로 저해될 수 있다. TIMPs는 화학량론에서 1:1로 특이적 결합하는 특이적 저해제이다. TIMP-1은 조직내에서 MMP-1의 중요한 저해제로 연관이 있다. TIMP-1의 활성을 측정하고자 CCD-986sk 세포에 UV-B를 조사한 후 추출물을 1, 5, 10 μg/mL의 농도별로 처리 후 48시간동안 배양하였다. 세포의 배양액을 취하여 TIMP-1의 활성을 측정하였으며, 그 결과를 도 25에 나타내었다.MMP activation can be specifically inhibited by tissue inhibitors of metallo-proteinase as well as non-specific inhibitors such as α2-macroglobulin and RECK. TIMPs are specific inhibitors that specifically bind 1: 1 in stoichiometry. TIMP-1 is an important inhibitor of MMP-1 in tissues. In order to measure the activity of TIMP-1, CCD-986sk cells were irradiated with UV-B, and the extracts were treated with 1, 5, and 10 μg / mL concentrations and cultured for 48 hours. The cell culture was taken and the activity of TIMP-1 was measured. The results are shown in FIG.
도 25에서와 같이 10 μg/mL의 처리 농도에서 잣외종피 물 추출물의 경우 74%, 알콜 추출물의 경우 75%의 비교적 높은 발현율을 확인하였다. 이러한 결과는 잣외종피 추출물의 처리에 의해 TIMP-1의 활성이 normal 군과 유사하게 회복됨으로서 MMP-1의 활성이 억제되어 collagen의 분해를 감소시키며 피부 조직의 탄력을 유지하고 주름 생성을 예방할 수 있을 것으로 판단되었다.
As shown in FIG. 25, at a treatment concentration of 10 μg / mL, a relatively high expression rate of 74% in the extract of Pine nuts and 75% in the alcohol extract was confirmed. These results indicate that TIMP-1 activity is restored to normal by the treatment of exocrine pine nut extract, so that the activity of MMP-1 is inhibited to reduce collagen degradation, maintain skin elasticity and prevent wrinkle formation Respectively.
제제예Formulation example 1. One. 화장료Cosmetics 제제의 제조 Manufacture of pharmaceutical preparations
유연화장수 제조Flexible longevity manufacturing
실시예 2의 잣외종피 추출물 0.1중량%, 1,3-부틸렌글리콜 5.2중량%, 올레일알코올 1.5중량%, 에탄올 3.2중량%, 폴리솔베이트 20 3.2중량%, 벤조페논-9 2.0중량%, 카르복실비닐폴리머 1.0중량%, 글리세린 3.5중량%, 미량의 향, 미량의 방부제 및 잔량의 정제수를 혼합하여 통상의 방법으로 유연화장수를 제조하였다.0.1% by weight of the extrudate extract of pine nut, 5.2% by weight of 1,3-butylene glycol, 1.5% by weight of oleyl alcohol, 3.2% by weight of ethanol, 3.2% by weight of
밀크로션Milk lotion 제조 Produce
실시예 2의 잣외종피 추출물 0.1중량%, 글리세린 5.1중량%, 프로필렌글리콜 4.2중량%, 토코페릴아세테이트 3.0중량%, 유동파라핀 4.6중량%, 트리에탄올아민 1.0중량%, 스쿠알란 3.1중량%, 마카다미아너트오일 2.5중량%, 폴리솔베이트 60 1.6중량%, 솔비탄세스퀴롤레이트 1.6중량%, 프로필파라벤 0.6중량%, 카르복실비닐폴리머 1.5중량%, 미량의 향, 미량의 방부제, 잔량의 정제수를 혼합하여 통상의 방법으로 밀크로션을 제조하였다.0.1% by weight of the extrudate extract of pine nut, 5.1% by weight of glycerin, 4.2% by weight of propylene glycol, 3.0% by weight of tocopheryl acetate, 4.6% by weight of liquid paraffin, 1.0% by weight of triethanolamine, 3.1% by weight of squalane, , 1.6% by weight of
영양크림 제조Nutrition cream manufacturing
실시예 2의 잣외종피 추출물 0.5중량%, 글리세린 4.0중량%, 바셀린 3.5중량%, 트리에탄올아민 2.1중량%, 유동파라핀 5.3중량%, 스쿠알란 3.0중량%, 밀납 2.6중량%, 토코페릴아세테이트 5.4중량%, 폴리솔베이트 60 3.2중량%, 카르복실비닐폴리머 1.0중량%, 솔비탄세스퀴올레이트 3.1중량%, 미량의 향, 미량의 방부제 및 잔량의 정제수를 혼합하여 통상의 방법으로 영양크림을 제조하였다.Example 2 was conducted in the same manner as in Example 2 except that 0.5% by weight of the extrudate extract of pine nut, 4.0% by weight of glycerin, 3.5% by weight of petroleum jelly, 2.1% by weight of triethanolamine, 5.3% by weight of liquid paraffin, 3.0% by weight squalane, 2.6% by weight of beeswax, 3.2% by weight of
마사지크림 제조Massage cream manufacturing
실시예 2의 잣외종피 추출물 0.5중량%, 글리세린 4.0중량%, 바셀린 3.5중량%, 트리에탄올아민 0.5중량%, 유동파라핀 24.0중량%, 스쿠알란 3.0중량%, 밀납 2.1중량%, 토코페릴아세테이트 0.1중량%, 폴리솔베이트 60 2.4중량%, 카르복실비닐폴리머 1.0중량%, 솔비탄세스퀴올레이트 2.3중량%, 미량의 향, 미량의 방부제 및 잔량의 정제수를 혼합하여 통상의 방법으로 마사지크림을 제조하였다.
Example 2 was conducted in the same manner as in Example 2 except that the pine nut extract of Example 2 was used in an amount of 0.5 wt%, glycerin 4.0 wt%, vaseline 3.5 wt%, triethanolamine 0.5 wt%, liquid paraffin 24.0 wt%, squalane 3.0 wt%, wax 2.1 wt%, tocopheryl acetate 0.1 wt% 2.4% by weight of
제제예Formulation example 2. 식품 제제의 제조 2. Manufacture of food preparation
건강식품 제조Health food manufacturing
실시예 2의 잣외종피 추출물 100㎎, 비타민 혼합물 적량, 비타민 A 아세테이트 70g, 비타민 E 1.0㎎, 비타민 B1 0.13㎎, 비타민 B2 0.15㎎, 비타민 B6 0.5㎎, 비타민 B12 0.2g, 비타민 C 10㎎, 비오틴 10g, 니코틴산아미드 1.7㎎, 엽산 50g, 판토텐산 칼슘 0.5㎎, 무기질 혼합물 적량, 황산제1철 1.75㎎, 산화아연 0.82㎎, 탄산마그네슘 25.3㎎, 제1인산칼륨 15㎎, 제2인산칼슘 55㎎, 구연산칼륨 90㎎, 탄산칼슘 100㎎ 및 염화마그네슘 24.8㎎을 혼합한 다음, 과립을 제조하고 통상의 방법에 따라 건강식품을 제조하였다. 이때, 상기 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하다.100 mg of pine nutritional extract of Example 2, a proper amount of vitamin A, 70 g of vitamin A acetate, 1.0 mg of vitamin E, 0.13 mg of vitamin B1, 0.15 mg of vitamin B2, 0.5 mg of vitamin B6, 0.2 g of vitamin B12, 10 mg of niacinamide, 1.7 mg of nicotinic acid amide, 50 g of folic acid, 0.5 mg of calcium pantothenate, 1.75 mg of ferrous sulfate, 0.82 mg of zinc oxide, 25.3 mg of magnesium carbonate, 15 mg of potassium phosphate monobasic, 90 mg of potassium citrate, 100 mg of calcium carbonate and 24.8 mg of magnesium chloride were mixed and granules were prepared and a health food was prepared according to a conventional method. At this time, although the composition ratio of the vitamin and mineral mixture is relatively mixed with the ingredient suitable for health food, it may be arbitrarily modified.
건강음료Health drink 제조 Produce
통상의 건강음료 제조방법에 따라 실시예 2의 잣외종피 추출물 100㎎, 비타민 C 15g, 비타민 E(분말) 100g, 젖산철 19.75g, 산화아연 3.5g, 니코틴산아미드 3.5g, 비타민 A 0.2g, 비타민 B1 0.25g, 비타민 B2 0.3g 및 정량의 물을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후 만들어진 용액을 여과하여 멸균된 2L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관하여 건강음료를 제조하였다. 이때, 상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.
100 mg of vitamin C, 100 g of vitamin E (powder), 19.75 g of iron lactate, 3.5 g of zinc oxide, 3.5 g of nicotinic acid amide, 0.2 g of vitamin A, 0.2 g of vitamin A B1, 0.3 g of vitamin B2 and a predetermined amount of water were mixed and heated at 85 DEG C for about 1 hour with stirring. The resulting solution was filtered and sterilized in a sterilized 2 L vessel, . At this time, although the composition ratio of the ingredients suitable for the beverage is comparatively mixed, the mixture ratio may be arbitrarily varied according to the demand, the demanded country, the intended use, and the regional or national preference.
제제예Formulation example 3. 약학 제제의 제조 3. Manufacture of pharmaceutical preparations
산제Powder 제조 Produce
실시예 2의 잣외종피 추출물 20㎎, 유당 100㎎ 및 탈트 10㎎을 혼합하고 기밀포에 충진하여 통상의 방법으로 산제를 제조하였다.20 mg of the crude extract of Pine nuts, 100 mg of lactose and 10 mg of talt were mixed and filled in an airtight container to prepare powders by a conventional method.
정제 제조Tablet manufacture
실시예 2의 잣외종피 추출물 10㎎, 옥수수전분 100㎎, 유당 100㎎ 및 스테아린산 마그네슘 2㎎을 혼합한 후 통상의 방법으로 타정하여 정제를 제조하였다.10 mg of pine nut extract of Example 2, 100 mg of corn starch, 100 mg of lactose and 2 mg of magnesium stearate were mixed and tableted by a conventional method.
캡슐제Capsule 제조 Produce
실시예 2의 잣외종피 추출물 10㎎, 결정성 셀룰로오스 3㎎, 락토오스 14.8㎎ 및 마그네슘 스테아레이트 0.2㎎을 혼합하고 통상의 방법으로 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.10 mg of pine nut extract of Example 2, 3 mg of crystalline cellulose, 14.8 mg of lactose and 0.2 mg of magnesium stearate were mixed and filled in gelatin capsules by a conventional method to prepare capsules.
주사제 제조Injection manufacturing
1앰플당(2mL) 실시예 2의 잣외종피 추출물 10㎎, 만니톨 180㎎, 주사용 멸균 증류수 2,974㎎ 및 Na2HPO4? 2H2O 26㎎으로 통상의 방법으로 주사제를 제조하였다.(2 mL) per ampoule: 10 mg of the crude extract of Example 2, 180 mg of mannitol, 2,974 mg of sterilized distilled water for injection, and Na 2 HPO 4 ? 2H 2 O (26 mg).
액제Liquid 제조 Produce
정제수에 실시예 2의 잣외종피 추출물 20㎎, 이성화당 10g 및 만니톨 5g을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합하였다. 그 다음 정제수를 더 가하여 전체 100mL로 조절한 후 갈색병에 충진하고 멸균시켜 통상의 방법으로 액제를 제조하였다.
To the purified water was added 20 mg of the pine nut extract of Example 2, 10 g of isomerized sugar and 5 g of mannitol and dissolved, and the lemon flavor was added in an appropriate amount, and the above components were mixed. Then, purified water was further added thereto, adjusted to a total volume of 100 mL, filled in a brown bottle, and sterilized to prepare a liquid preparation by a conventional method.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140105250A KR101570123B1 (en) | 2014-08-13 | 2014-08-13 | Cosmetic Composition Comprising Extract of testa of Pinus koraiensis Siebold et Zucc |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140105250A KR101570123B1 (en) | 2014-08-13 | 2014-08-13 | Cosmetic Composition Comprising Extract of testa of Pinus koraiensis Siebold et Zucc |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150129211A Division KR101774860B1 (en) | 2015-09-11 | 2015-09-11 | A Cosmetic Composition for Whitening or Pore-Minimizing Comprising Extract of testa of Pinus koraiensis Siebold et Zucc |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101570123B1 true KR101570123B1 (en) | 2015-11-27 |
Family
ID=54847730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020140105250A KR101570123B1 (en) | 2014-08-13 | 2014-08-13 | Cosmetic Composition Comprising Extract of testa of Pinus koraiensis Siebold et Zucc |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101570123B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102085679B1 (en) | 2019-07-31 | 2020-03-06 | 조선대학교 산학협력단 | New compounds and cosmetic composition including the same |
-
2014
- 2014-08-13 KR KR1020140105250A patent/KR101570123B1/en active IP Right Grant
Non-Patent Citations (2)
Title |
---|
Packer, Lester 저, The Antioxidant Miracle (1999.) |
김화선. 서울과학기술대학교 산업대학원 석사학위논문. 키토산과 잣잎, 잣껍질 추출물의 항산화 및 항균할성. (2013.02.) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102085679B1 (en) | 2019-07-31 | 2020-03-06 | 조선대학교 산학협력단 | New compounds and cosmetic composition including the same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102282748B1 (en) | Composition for skin cell regeneration, anti-wrinkle, anti-inflammation, or skin whitening | |
KR20130083805A (en) | Composition for enhancing elasticity and whitening | |
KR101510092B1 (en) | A composition comprising the seed extract of Rubus coreanus M for preventing and treating skin aging and for skin whitening | |
KR101774867B1 (en) | A Cosmetic Composition for Whitening or Pore-Minimizing Comprising Extract of cone scale of Pinus koraiensis Siebold et Zucc | |
KR101628282B1 (en) | Composition for skin-whitening comprising Arbutin derivative | |
KR20160121074A (en) | A composition comprising an seed extract of Vitex trifolia L. for skin whitening and anti-aging activity | |
KR101458013B1 (en) | Composition for anti-oxidation and whitening and anti-wrinkle cosmetics comprising extract of un-ripening Pinus koraiensis Siebold et Zucc cone | |
KR100894714B1 (en) | Extract of humata tyermanni moore having skin whitening and anti-oxidative activation | |
KR20140086747A (en) | Health Functional Food Composition Comprising Red Ginseng Extract, Benincasa Hispida Extract, and Apios Americana Extract for Improving Skin Beauty | |
KR101570123B1 (en) | Cosmetic Composition Comprising Extract of testa of Pinus koraiensis Siebold et Zucc | |
KR20120036011A (en) | Composition comprising a leaf extract of isatis tinctoria l. showing skin whitening and anti-wrinkle activity | |
KR20190063171A (en) | Composition comprising extract of solanum nigrum or solsonine as an effective ingredient for preventing skin aging or improving skin wrinkle | |
KR20150087141A (en) | Composition for improving skin | |
KR20080104760A (en) | Composition comprising an extract of magnolia officinalis rehd. et wils. or 4-o-methylhonokiol compound isolated therefrom for skin whitening | |
KR102604373B1 (en) | Improvement composition for Hot flash comprising the extract of Salvia miltiorrhiza as an active ingredient | |
KR101774860B1 (en) | A Cosmetic Composition for Whitening or Pore-Minimizing Comprising Extract of testa of Pinus koraiensis Siebold et Zucc | |
KR20210134589A (en) | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom | |
KR20160020384A (en) | Cosmetic Composition Comprising Extract of cone scale of Pinus koraiensis Siebold et Zucc | |
KR101570121B1 (en) | Cosmetic Composition Comprising Extract of cone scale of Pinus koraiensis Siebold et Zucc | |
KR101971679B1 (en) | Tyrosinase inhibition and whitening activity of solvent extract of Desmodium sequax Wall or a fraction thereof | |
KR100756669B1 (en) | Cosmetic composition comprising an extract of Persicae fructus having whitening activities | |
KR101720712B1 (en) | Composition for improving skin comprising levistilide A | |
KR102183896B1 (en) | Composition for improving skin | |
KR101655395B1 (en) | Cosmetic compositions comprising extracts of Platycarya strobilacea | |
KR100622286B1 (en) | Skin whitening composition comprising 5-hydroxytryptophan as an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20180921 Year of fee payment: 4 |